var title_f33_51_34608="XRT proctitis APC Endosc";
var content_f33_51_34608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Radiation telangiectasias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Endoscopy shows hemorrhagic areas in the rectum in a patient with radiation telangiectasias and chronic hematochezia. Right panel: The hemorrhagic areas have been treated with argon plasma coagulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Cohen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34608=[""].join("\n");
var outline_f33_51_34608=null;
var title_f33_51_34609="Lupus panniculitis facial lipoatrophy";
var content_f33_51_34609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lupus panniculitis (lupus profundus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lipoatrophy is present on the face of this patient with lupus panniculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34609=[""].join("\n");
var outline_f33_51_34609=null;
var title_f33_51_34610="Uterosacral ligm plication2";
var content_f33_51_34610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterosacral ligament plication during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34610=[""].join("\n");
var outline_f33_51_34610=null;
var title_f33_51_34611="Brain anatomy PI";
var content_f33_51_34611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    The anatomy of the brain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 564px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34611=[""].join("\n");
var outline_f33_51_34611=null;
var title_f33_51_34612="Ketoconazole (topical): Patient drug information";
var content_f33_51_34612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketoconazole (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38500?source=see_link\">",
"     see \"Ketoconazole (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=see_link\">",
"     see \"Ketoconazole (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8120613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Extina&reg;;",
"     </li>",
"     <li>",
"      Nizoral&reg;;",
"     </li>",
"     <li>",
"      Nizoral&reg; A-D [OTC];",
"     </li>",
"     <li>",
"      Xolegel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketoderm&reg;;",
"     </li>",
"     <li>",
"      Xolegel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dandruff.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ketoconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scalp irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698310",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Takes curl out of hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream, foam, and gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin, cream, foam, and gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not place foam or gel right in hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid fire, flames, or smoking until the foam or gel has dried.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin, shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet hair and scalp or skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on enough shampoo to make a lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lather well and leave on as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store cream, foam, gel, and shampoo at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699254",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect foam and shampoo from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3013919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect foam and gel from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12234 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34612=[""].join("\n");
var outline_f33_51_34612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120613\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120614\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031285\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031284\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031289\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031290\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031292\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031287\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031288\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031293\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031294\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/58/28585?source=related_link\">",
"      Ketoconazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/30/2533?source=related_link\">",
"      Ketoconazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/62/20457?source=related_link\">",
"      Ketoconazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38500?source=related_link\">",
"      Ketoconazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=related_link\">",
"      Ketoconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_51_34613="Sweet syndrome - histopathology";
var content_f33_51_34613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dense neutrophilic infiltrate in Sweet syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34613=[""].join("\n");
var outline_f33_51_34613=null;
var title_f33_51_34614="Plasma cell infiltrate AASLD";
var content_f33_51_34614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma cell infiltrate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plasma cells are identified by their eccentric, clock-face nucleus and pale perinuclear cytoplasmic crescent. They are characteristic of autoimmune hepatitis, but neither pathognomonic of the disease or required for its diagnosis. Staining by hematoxylin-eosin; original magnification x 400.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2002; 36:479.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34614=[""].join("\n");
var outline_f33_51_34614=null;
var title_f33_51_34615="Evaluation of headache in adults";
var content_f33_51_34615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of headache in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     R Joshua Wootton, MDiv, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34615/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/51/34615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is among the most common medical complaints. An overview of the approach to the patient with headache is presented here. The approach to adults presenting with headache in the emergency department is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=see_link\">",
"     \"Evaluation of the adult with headache in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and management of specific primary headache syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND CLASSIFICATION OF HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many controversies exist in the literature regarding the nomenclature and classification of headache. The International Headache Society (IHS) classification and diagnostic criteria for headache were revised in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/1\">",
"     1",
"    </a>",
"    ]. This system gives operational diagnostic criteria for headaches, cranial neuralgias, and facial pain syndromes. The IHS classification also details which clinical features must be present and in what combination to establish a precise diagnosis. However, this classification system can be cumbersome for day to day use. The IHS criteria may be most useful for grouping patients for scientific purposes, such as clinical trials and epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As many as 90 percent of all benign headaches fall under a few categories, including migraine, tension-type, and cluster headache. While a population-based study found that the one-year prevalence of episodic tension-type headache was 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/3\">",
"     3",
"    </a>",
"    ], most of these people do not present to physicians for care. As an example, a study of two primary care units in Brazil found that migraine was the most prevalent primary headache disorder, accounting for 45 percent of patients reporting headache as a single symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cluster headache typically leads to significant disability and most of these patients will come to medical attention. However, cluster headache remains an uncommon diagnosis in primary care settings because of overall low prevalence in the general population (&lt;1 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link&amp;anchor=H3#H3\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians can easily become familiar with the most common headache disorders and how to differentiate between them (",
"    <a class=\"graphic graphic_table graphicRef68064 \" href=\"mobipreview.htm?40/58/41899\">",
"     table 1",
"    </a>",
"    ). It is not necessary to follow the detailed classification and diagnostic criteria proposed by the IHS, although there are certain important points that should be kept in mind whenever describing, managing, or discussing patients with headache:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not appropriate to use the term vascular headaches to describe migraine and cluster headaches, nor is it correct to use the term muscle contraction headaches to describe common headache types that are without typical migrainous or other autonomic features.",
"     </li>",
"     <li>",
"      Although often attributed to muscle contraction, the exact mechanism of tension-type headache is unknown. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link&amp;anchor=H3#H3\">",
"       \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\", section on 'Pathophysiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Headache due to vascular abnormalities, aneurysm, or arteriovenous malformation should be described separately from migraine or cluster headaches since these are different diseases pathophysiologically, and the management strategies are different.",
"     </li>",
"     <li>",
"      Use of the term \"psychogenic headache\" should be discouraged since it tends to be confusing to patients and wrongly suggests that organic processes are not involved. However, the revised 2004 IHS criteria do have a category of headache attributed to psychiatric disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other disorders may cause headaches. In the Brazilian primary care study, 39 percent of patients presenting with headache had a headache that was due to a systemic disorder (most commonly fever, acute hypertension, and sinusitis), and 5 percent had a headache that was due to a neurologic disorder (most commonly posttraumatic headache, headaches secondary to cervical spine disease, and expansive intracranial processes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/4\">",
"     4",
"    </a>",
"    ]. Physicians who evaluate patients with headache should be alert to signs that suggest a serious underlying disorder (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Danger signs on history'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients frequently attribute headaches to eye strain, and the IHS recognizes headaches associated with refractive errors (HARE). However, an observational study suggested that headaches are only rarely due to refractive error alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/5\">",
"     5",
"    </a>",
"    ]. Nevertheless, correcting vision may improve headache symptoms in some of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEADACHE TRIGGERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies have identified many potential triggers that may start an attack or worsen a preexisting headache. The role of most of these headache triggers has been well established in terms of migraine but remains less clear for other headache types. A partial list appears in Table 2 (",
"    <a class=\"graphic graphic_table graphicRef57424 \" href=\"mobipreview.htm?36/42/37548\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is a common belief, particularly among patients, that hypertension can cause headaches. While this is true in the case of hypertensive emergencies, it is probably not true for typical migraine or tension headaches. As an example, a report from the Physicians' Health Study of 22,701 American male physicians ages 40 to 84 years analyzed various risk factors for cerebrovascular disease and found no difference in the percentage of men with a history of hypertension in the migraine and nonmigraine groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, a prospective study of 22,685 adults in Norway found that high systolic and diastolic pressures were actually associated with a reduced risk of nonmigrainous headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these studies, a meta-analysis of 95 randomized controlled trials examining antihypertensive treatment with four different medication classes found that patients assigned to blood pressure treatment had a significant reduction in headache prevalence compared with placebo treatment, and that headache prevalence was significantly reduced in each of the four classes of drugs compared individually with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/8\">",
"     8",
"    </a>",
"    ]. These results suggest that hypertension plays a role in headache pathogenesis. However, the study is limited by the lack of data regarding headache classification, and it is possible that many of the patients reporting headache had migraine, which is known to be responsive to many different antihypertensive medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link&amp;anchor=H4#H4\">",
"     \"Preventive treatment of migraine in adults\", section on 'Antihypertensives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF THE HEADACHE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluating a patient with new onset headache pain can be challenging. It requires a systematic approach based upon an understanding of the common headache syndromes. Making a correct diagnosis is the first and foremost step in the proper management of headache patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic case history is the single most important factor in establishing a headache diagnosis and determining the future work-up and treatment plan. A thorough history also helps focus the physical examination and prevent unnecessary investigation and imaging studies.",
"   </p>",
"   <p>",
"    A systematic case history should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age at onset",
"     </li>",
"     <li>",
"      Presence or absence of aura and prodrome",
"     </li>",
"     <li>",
"      Frequency, intensity and duration of attack",
"     </li>",
"     <li>",
"      Number of headache days per month",
"     </li>",
"     <li>",
"      Time and mode of onset",
"     </li>",
"     <li>",
"      Quality, site, and radiation of pain",
"     </li>",
"     <li>",
"      Associated symptoms and abnormalities",
"     </li>",
"     <li>",
"      Family history of migraine",
"     </li>",
"     <li>",
"      Precipitating and relieving factors",
"     </li>",
"     <li>",
"      Effect of activity on pain",
"     </li>",
"     <li>",
"      Relationship with",
"      <span class=\"nowrap\">",
"       food/alcohol",
"      </span>",
"     </li>",
"     <li>",
"      Response to any previous treatment",
"     </li>",
"     <li>",
"      Any recent change in vision",
"     </li>",
"     <li>",
"      Association with recent trauma",
"     </li>",
"     <li>",
"      Any recent changes in sleep, exercise, weight, or diet",
"     </li>",
"     <li>",
"      State of general health",
"     </li>",
"     <li>",
"      Change in work or lifestyle (disability)",
"     </li>",
"     <li>",
"      Change in method of birth control (women)",
"     </li>",
"     <li>",
"      Possible association with environmental factors",
"     </li>",
"     <li>",
"      Effects of menstrual cycle and exogenous hormones (women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, the most common headache syndromes frequently present with characteristic symptoms (",
"    <a class=\"graphic graphic_table graphicRef68064 \" href=\"mobipreview.htm?40/58/41899\">",
"     table 1",
"    </a>",
"    ). However, there may be considerable symptom overlap; one population-based survey found that less than one-half of patients who complained of headaches that met the IHS criteria for migraine were properly diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/9\">",
"     9",
"    </a>",
"    ]. Migraine symptoms may also overlap with other causes of headache. As an example, a significant number of patients with migraine may have nasal symptoms that suggest sinus disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/10\">",
"     10",
"    </a>",
"    ]; in addition, a study of primary care patients with recurrent sinus headache found that 90 percent experienced attacks that met the IHS criteria for migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H17#H17\">",
"     \"Headache syndromes other than migraine\", section on 'Sinus headache'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diagnostic instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the pitfalls described above, a number of diagnostic instruments have been proposed, primarily to assist with the diagnosis of migraine, the most common primary headache syndrome in patients presenting to primary care physicians. A simple and recently validated instrument, the brief headache screen, appears to be well suited to identify migraine in the primary care setting. Different versions of the brief headache screen have been promoted, including anywhere from three to six questions. A version adopted by the American Academy of Neurology includes the following four questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How often do you get severe headaches (ie, without treatment it is difficult to function)?",
"     </li>",
"     <li>",
"      How often do you get other (milder) headaches?",
"     </li>",
"     <li>",
"      How often do you take headache relievers or pain pills?",
"     </li>",
"     <li>",
"      Has there been any recent change in your headaches?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one validation study, the presence of episodic disabling headache correctly identified migraine in 136 of 146 patients (93 percent) with episodic migraine, and 154 of 197 patients (78 percent) with chronic headache with migraine, with a specificity of 63 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/12\">",
"     12",
"    </a>",
"    ]. Only 6 of 343 patients (1.7 percent) with migraine were not identified by disabling headache. Thus, virtually any patient with severe episodic headaches can be considered to have migraine.",
"   </p>",
"   <p>",
"    Questions 2 and 3 can be helpful for identifying patients with medication overuse (eg, patients who use symptomatic medications more than three days per week",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who have daily headaches). Question 4 is particularly helpful for identifying patients who may have an important secondary cause of headache; a patient with a stable pattern of headache for six months is unlikely to have a serious underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Danger signs on history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paying attention to danger signs is important since headaches may be the presenting symptom of a space-occupying mass or vascular lesion, infection, metabolic disturbance, or a systemic problem. The following features in the history can serve as warning signs of possible serious underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=see_link\">",
"     \"Evaluation of the adult with headache in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden onset of headache, or severe persistent headache that reaches maximal intensity within a few",
"      <strong>",
"       seconds",
"      </strong>",
"      or",
"      <strong>",
"       minutes",
"      </strong>",
"      after the onset of pain, warrants aggressive investigation. Subarachnoid hemorrhage, for example, often presents with the abrupt onset of excruciating pain. In contrast, migraine headaches generally begin with moderate pain and then gradually increase to a maximal level over one to two hours. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cluster headache may sometimes be confused with a serious headache, since the pain from a cluster headache can reach full intensity within minutes. However, cluster headache is transient (usually lasting less than one to two hours) and is associated with characteristic ipsilateral autonomic signs such as tearing or rhinorrhea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The absence of similar headaches in the past is another finding that suggests a possible serious disorder. The \"first\" or \"worst\" headache of my life is a description that sometimes accompanies an intracranial hemorrhage or central nervous system (CNS) infection. On the other hand, patients suffering from migraine usually have had similar types of headaches in the past.",
"     </li>",
"     <li>",
"      A worsening pattern of headache suggests a mass lesion, subdural hematoma, or medication overuse headache. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H8#H8\">",
"       \"Headache syndromes other than migraine\", section on 'Medication overuse headache'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Focal neurologic symptoms other than typical visual or sensory aura should raise suspicion for a mass lesion, arteriovenous malformation, or collagen vascular disease.",
"     </li>",
"     <li>",
"      Fever associated with headache may be caused by intracranial, systemic, or local infection, as well as other etiologies (",
"      <a class=\"graphic graphic_table graphicRef80966 \" href=\"mobipreview.htm?31/19/32059\">",
"       table 3",
"      </a>",
"      ). Infection in a non-intracranial location (such as the lungs or paranasal or mastoid sinuses) may serve as a nidus for the development of meningitis or intracranial abscess. Fever is not a characteristic of migraine headache; it may, however, follow a subarachnoid hemorrhage by a few days.",
"     </li>",
"     <li>",
"      Any change in mental status, personality, or fluctuation in the level of consciousness suggests a potentially serious abnormality.",
"     </li>",
"     <li>",
"      The rapid onset of headache with strenuous exercise, especially when minor trauma has occurred, raises the possibility of carotid artery dissection or intracranial hemorrhage.",
"     </li>",
"     <li>",
"      Head pain that spreads into the lower neck and between the shoulders may indicate meningeal irritation due to either infection or subarachnoid blood; it is not typical of a benign process.",
"     </li>",
"     <li>",
"      New headache in patients under the age of 5 or over the age of 50 may suggest underlying pathology.",
"     </li>",
"     <li>",
"      New headache type in a patient with cancer suggests metastasis.",
"     </li>",
"     <li>",
"      New headache type in a patient with Lyme disease suggests meningoencephalitis.",
"     </li>",
"     <li>",
"      New headache type in a patient with HIV suggests an opportunistic infection or tumor.",
"     </li>",
"     <li>",
"      Headache during pregnancy or postpartum suggests possible cortical vein or venous sinus thrombosis, carotid dissection, and pituitary apoplexy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other features suggesting a specific headache source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other features that suggest a specific source of headache pain include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic nasal stuffiness or chronic respiratory infection suggests a diagnosis of sinusitis, although, as mentioned above, patients with migraine may also have nasal symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H17#H17\">",
"       \"Headache syndromes other than migraine\", section on 'Sinus headache'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Impaired vision or seeing \"holes\" around light suggests the presence of glaucoma. Suspicion for subacute angle closure glaucoma should be raised by relatively short duration (often less than one hour) unilateral headaches that do not meet criteria for migraine arising after age 50 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Visual field defects suggest the presence of a lesion of the optic pathway (eg, due to a pituitary mass).",
"     </li>",
"     <li>",
"      Blurring of vision on forward bending of the head, headaches upon waking early in the morning that improve with sitting up, and double vision or loss of coordination and balance should raise the suspicion of raised intracranial pressure; this disorder should also be considered in patients with chronic, daily, progressively worsening headaches associated with chronic nausea.",
"     </li>",
"     <li>",
"      In patients who present with headache that is relieved with recumbency and exacerbated with upright posture, the diagnosis of low cerebrospinal fluid (CSF) pressure headache should be considered. An additional major feature of this headache syndrome is diffuse meningeal enhancement on brain MRI. The accepted etiology is CSF leakage, which may occur in the context of rupture of an arachnoid membrane. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/20/330?source=see_link\">",
"       \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of nausea, vomiting, worsening of headache with changes in body position (particularly bending over), an abnormal neurologic examination,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a significant change in prior headache pattern suggest the headache was caused by a tumor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sudden, severe, unilateral vision loss suggests the presence of optic neuritis.",
"     </li>",
"     <li>",
"      Headache, fatigue, generalized aches and pain, and night sweats in subjects age 55 years or older suggest the presence of temporal arteritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"       \"Diagnosis of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intermittent headaches with high blood pressure are suggestive of pheochromocytoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with headache complaints have a completely normal physical and neurologic examination. If a complete and careful history does not point to an organic etiology, further examination is warranted in the following areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain blood pressure and pulse",
"     </li>",
"     <li>",
"      Listen for bruit at neck, eyes, and head for clinical signs of arteriovenous malformation",
"     </li>",
"     <li>",
"      Palpate the head, neck, and shoulder regions",
"     </li>",
"     <li>",
"      Check temporal and neck arteries",
"     </li>",
"     <li>",
"      Examine the spine and neck muscles",
"     </li>",
"     <li>",
"      A functional neurologic examination including getting up from a seated position without any support, walking on tiptoes and heels, cranial nerve examination, funduscopy and otoscopy, tandem gait and Romberg test, and symmetry on motor, sensory, reflex and cerebellar (coordination) tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Danger signs on examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs on examination that suggest serious pathology include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/14\">",
"     14",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of the adult with headache in the emergency department\", section on 'High-risk examination findings'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neck stiffness and especially meningismus (resistance to passive neck flexion) suggests meningitis.",
"     </li>",
"     <li>",
"      Papilledema suggests the presence of an intracranial mass lesion, benign intracranial hypertension (pseudotumor cerebri), encephalitis, or meningitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17417?source=see_link\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Focal neurologic signs suggest an intracranial mass lesion, arteriovenous malformation, or collagen vascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indications for imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with any of the danger signs noted above need urgent brain imaging. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Danger signs on history'",
"    </a>",
"    above.) In the remaining patients, there are no randomized, controlled trials that help delineate when imaging is necessary, and no such trials are likely to be forthcoming as blinding and randomization would present ethical problems. As a result, the decision to scan or not to scan in headache is likely to remain one of clinical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of patients without danger signs do not have secondary causes of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As an example, in a study of 373 patients with chronic headache at a tertiary referral center, all had one or more of the following characteristics that prompted referral for head CT scanning: increased severity of symptoms or resistance to appropriate drug therapy; change in characteristics or pattern of headache; or family history of an intracranial structural lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/20\">",
"     20",
"    </a>",
"    ]. Only four scans (1 percent) showed significant lesions (two osteomas, one low grade glioma, and one aneurysm); only the aneurysm was treated.",
"   </p>",
"   <p>",
"    The American Academy of Neurology, American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine, and four other groups formed a consortium and issued a year 2000 practice guideline that came to the following conclusions regarding the need for brain imaging in patients with headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroimaging should be considered in patients with nonacute headache and an unexplained abnormal finding on neurologic examination.",
"     </li>",
"     <li>",
"      Evidence is insufficient to make specific recommendations in the presence or absence of neurologic symptoms (eg, headache worsened by Valsalva, causing awakening from sleep, new headache in older population, or progressively worsening headache).",
"     </li>",
"     <li>",
"      Neuroimaging is usually not warranted for patients with migraine and a normal neurologic examination, although a lower threshold for imaging is warranted in patients with atypical migraine features or in patients who do not fulfill the strict definition of migraine.",
"     </li>",
"     <li>",
"      Data were insufficient to make a specific recommendation for patients with tension-type headache.",
"     </li>",
"     <li>",
"      Data were insufficient to make a specific recommendation regarding the relative sensitivity of MRI compared with CT in patients who have an imaging study performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the lack of definitive data, one approach is to consider neuroimaging in the following situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent significant change in the pattern, frequency or severity of headaches",
"     </li>",
"     <li>",
"      Progressive worsening of headache despite appropriate therapy",
"     </li>",
"     <li>",
"      Focal neurologic signs or symptoms",
"     </li>",
"     <li>",
"      Onset of headache with exertion, cough, or sexual activity",
"     </li>",
"     <li>",
"      Orbital bruit",
"     </li>",
"     <li>",
"      Onset of headache after age 40 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may also be reasonable to image a patient presenting with nonmigrainous featureless headache, ie, bilateral nonthrobbing headache without nausea and without sensitivity to light, sound, or smell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/17\">",
"     17",
"    </a>",
"    ]. Such an approach would have an estimated yield of 2 percent for detecting a treatable cause.",
"   </p>",
"   <p>",
"    Brain imaging for no other reason than reassurance is sometimes performed in clinical practice. In the end, patients are seeking a reason for the problem. It is important that the clinician provide the patient with a clear explanation of both the diagnosis and the reason for the brain scan, especially if the decision is made to obtain imaging in someone suspected of having primary headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data are insufficient to recommend CT or MRI when neuroimaging is deemed necessary. A head CT scan (without and with contrast) is likely to be sufficient in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34615/abstract/23\">",
"     23",
"    </a>",
"    ]. An MRI along with MRA are indicated when posterior fossa or vascular lesions are suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Indications for lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture (LP) for cerebrospinal fluid analysis is urgently indicated in patients with headache when there is clinical suspicion of subarachnoid hemorrhage in the setting of a negative or normal head CT scan. In addition, LP is indicated when there is clinical suspicion of an infectious or inflammatory etiology of headache. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19561?source=see_link&amp;anchor=H3#H3\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While episodic tension-type headache is common in population-based studies, migraine is the most common diagnosis in patients presenting to primary care physicians with headache. The appropriate evaluation of headache complaints includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rule out serious underlying pathology and look for other secondary causes of headache. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Danger signs on history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Danger signs on examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determine the type of primary headache using the patient history as the primary diagnostic tool (",
"      <a class=\"graphic graphic_table graphicRef68064 \" href=\"mobipreview.htm?40/58/41899\">",
"       table 1",
"      </a>",
"      ). There may be overlap in symptoms, particularly between migraine and tension-type headache and between migraine and some secondary causes of headache (such as sinus disease). Use of an instrument such as the brief headache screen appears to be helpful in identifying patients with migraine in particular. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnostic instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An imaging study is not necessary in the vast majority of patients presenting with headache. Nevertheless, imaging (usually CT scan) is warranted in the patients outlined above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications for imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/2\">",
"      Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia 1991; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/3\">",
"      Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 1998; 279:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/4\">",
"      Bigal ME, Bordini CA, Speciali JG. Etiology and distribution of headaches in two Brazilian primary care units. Headache 2000; 40:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/5\">",
"      Gil-Gouveia R, Martins IP. Headaches associated with refractive errors: myth or reality? Headache 2002; 42:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/6\">",
"      Buring JE, Hebert P, Romero J, et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 1995; 52:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/7\">",
"      Hagen K, Stovner LJ, Vatten L, et al. Blood pressure and risk of headache: a prospective study of 22 685 adults in Norway. J Neurol Neurosurg Psychiatry 2002; 72:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/8\">",
"      Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation 2005; 112:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/9\">",
"      Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/10\">",
"      Barbanti P, Fabbrini G, Pesare M, et al. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 2002; 22:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/11\">",
"      Cady RK, Schreiber CP. Sinus headache: a clinical conundrum. Otolaryngol Clin North Am 2004; 37:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/12\">",
"      Maizels M, Burchette R. Rapid and sensitive paradigm for screening patients with headache in primary care settings. Headache 2003; 43:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/13\">",
"      Edmeads J. Emergency management of headache. Headache 1988; 28:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/14\">",
"      Lipton RB, Bigal ME, Steiner TJ, et al. Classification of primary headaches. Neurology 2004; 63:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/15\">",
"      Lynch KM, Brett F. Headaches that kill: a retrospective study of incidence, etiology and clinical features in cases of sudden death. Cephalalgia 2012; 32:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/16\">",
"      Shindler KS, Sankar PS, Volpe NJ, Piltz-Seymour JR. Intermittent headaches as the presenting sign of subacute angle-closure glaucoma. Neurology 2005; 65:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/17\">",
"      Goadsby PJ. To scan or not to scan in headache. BMJ 2004; 329:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/18\">",
"      Tsushima Y, Endo K. MR imaging in the evaluation of chronic or recurrent headache. Radiology 2005; 235:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/19\">",
"      You JJ, Gladstone J, Symons S, et al. Patterns of care and outcomes after computed tomography scans for headache. Am J Med 2011; 124:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/20\">",
"      Dumas MD, Pexman JH, Kreeft JH. Computed tomography evaluation of patients with chronic headache. CMAJ 1994; 151:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/21\">",
"      Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000; 54:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/22\">",
"      Kumar KL, Cooney TG. Headaches. Med Clin North Am 1995; 79:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34615/abstract/23\">",
"      Kent DL, Haynor DR, Longstreth WT Jr, Larson EB. The clinical efficacy of magnetic resonance imaging in neuroimaging. Ann Intern Med 1994; 120:856.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3349 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-7A5059B635-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34615=[""].join("\n");
var outline_f33_51_34615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND CLASSIFICATION OF HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEADACHE TRIGGERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRINCIPLES OF THE HEADACHE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diagnostic instruments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Danger signs on history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other features suggesting a specific headache source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Danger signs on examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indications for imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Indications for lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3349\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3349|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/58/41899\" title=\"table 1\">",
"      Common headache syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/42/37548\" title=\"table 2\">",
"      Headache triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/19/32059\" title=\"table 3\">",
"      Diff dx headache with fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=related_link\">",
"      Evaluation of the adult with headache in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_51_34616="Epidemiology and clinical manifestations of invasive aspergillosis";
var content_f33_51_34616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of invasive aspergillosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34616/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34616/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34616/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34616/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34616/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/51/34616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"aspergillosis\" refers to illness due to allergy, airway or lung invasion, cutaneous infection, or extrapulmonary dissemination caused by species of Aspergillus, most commonly A. fumigatus, A. flavus, and A. terreus. Aspergillus species are ubiquitous in nature, and inhalation of infectious conidia is a frequent event. Tissue invasion is uncommon and occurs most frequently in the setting of immunosuppression associated with therapy for hematologic malignancies, hematopoietic cell transplantation, or solid organ transplantation.",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, and clinical manifestations and diagnosis of invasive aspergillosis will be reviewed here. The diagnosis and treatment of invasive aspergillosis are discussed separately; other syndromes caused by Aspergillus species, including invasive aspergillosis in HIV-infected patients, are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31529?source=see_link\">",
"     \"Treatment of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35270?source=see_link\">",
"     \"Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11178?source=see_link\">",
"     \"Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354394\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled conidia are met by the innate defenses provided by resident phagocytes, specifically, airway epithelial cells and alveolar macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Little is known about the contribution of epithelial cells in clearing conidia. Relatively more is known about macrophages, which contribute to both conidial clearance and the production of secondary inflammation. These cells secrete inflammatory mediators after recognition of key cell wall components (eg, beta-D-glucan) exposed after conidial germination into hyphal forms. These mediators result in neutrophil recruitment and the activation of cellular immunity, which are important in killing potentially invasive microbial forms (hyphae) and determining the extent and nature of the immune response. Hence, risks for disease and the type of disease that occurs are the combined result of multiple cellular functions that impact proximal events in conidial clearance, production of inflammation, and killing of invasive forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microbial factors that impact disease potential include toxins, proteases, and secondary metabolites that exert multiple effects on the host&rsquo;s local pulmonary and systemic defense. These include cellular products that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibit phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, a key component in host defense against filamentous fungi",
"     </li>",
"     <li>",
"      Inhibit macrophage phagocytosis and killing",
"     </li>",
"     <li>",
"      Suppress functional T-cell responses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histopathologically, invasive aspergillosis is characterized by progression of the infection across tissue planes. One hallmark of infection is vascular invasion with subsequent infarction and tissue necrosis. Presumably, fungal cell surface components bind to vessel wall components including basement membrane, extracellular matrix, and cellular constituents, and can cause ischemia and infarction of structures distal to invaded arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIAL EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429408\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, mycologists utilized phenotypic characteristics to identify Aspergillus organisms to the species level; more recently, use of molecular methods has expanded the number of recognized species and increased our knowledge of the organism&rsquo;s pathogenicity and other characteristics.",
"   </p>",
"   <p>",
"    Members of the genus Aspergillus are broken into multiple subgenera, each of which contains multiple sections and species. Some species are not distinguishable based on phenotypic typing. More recently recognized species that have variable susceptibilities and behaviors in vivo have been implicated in disease worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/3\">",
"     3",
"    </a>",
"    ]. Given the complexity of the classification scheme, and lack of routine molecular typing, it has recently been suggested that isolates be referred to as being members of a \"species complex.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429415\">",
"    <span class=\"h2\">",
"     Species prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most invasive infections are caused by members of the A. fumigatus species complex. In a report of 218 infections in 24 transplant centers in the United States, 67 percent were caused by members of the A. fumigatus complex, followed by A. flavus (13 percent), A. niger (9 percent), and A. terreus (7 percent). These data contrast with epidemiologic data from a decade earlier when the vast majority of cases (90 percent) were secondary to A. fumigatus species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/4\">",
"     4",
"    </a>",
"    ], likely reflecting changes in microbial epidemiology, center-based differences,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    changes in typing methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying conditions that compromise pulmonary and systemic immune responses to inhaled Aspergillus species serve as risk factors for invasive pulmonary aspergillosis.",
"   </p>",
"   <p>",
"    Classic risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe and prolonged neutropenia",
"     </li>",
"     <li>",
"      Receipt of high doses of glucocorticoids",
"     </li>",
"     <li>",
"      Other drugs or conditions that lead to chronically impaired cellular immune responses (eg, immunosuppressive regimens administered to treat autoimmune diseases and to prevent organ rejection, and AIDS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Invasive disease is most frequent when there is a high amount of airway exposure, for instance, in the setting of construction, or when the host has a condition in which conidia are not effectively cleared. Historically, the highest risks for invasive infections have been seen in severely immunosuppressed patients, particularly allogeneic hematopoietic cell transplant (HCT) or solid organ transplant (especially lung, heart-lung, and liver) recipients, and patients who experience prolonged durations of neutropenia. There are some inherited immunodeficiencies, such as chronic granulomatous disease, that lead to high risk for pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/1\">",
"     1",
"    </a>",
"    ]. Mannose-binding lectin deficiency has also been associated with invasive aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19690?source=see_link\">",
"     \"Mannose-binding lectin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data suggest that invasive aspergillosis can also occur in less immunosuppressed hosts in the intensive care unit setting, particularly those with underlying chronic obstructive pulmonary disease (COPD) receiving glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The nature of the immune suppression (the degree, duration, and type of immunodeficiency) influences the pathogenesis of disease; aspergillosis thus manifests as a spectrum of disease involving predominantly airway (eg, tracheobronchitis), lung, or both.",
"   </p>",
"   <p>",
"    There are specific risk factors that are unique to patients with various underlying diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HCT recipients, persistent neutropenia, severe graft versus host disease (and accompanying therapies), and cytomegalovirus (CMV) infection are risks factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variability in genes encoding molecules that mediate innate immunity also increases the risk of invasive aspergillosis. Polymorphisms in genes encoding plasminogen in HCT recipients and the toll-like receptor 4 gene in HCT donors have been described as genetic risks in recipients of allogeneic HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. A polymorphism in the gene encoding dectin-1, a C-type lectin involved in recognizing beta-D-glucan, also appears to increase the risk of invasive aspergillosis in immunocompromised hosts, with two studies demonstrating increased risks in patients with hematologic malignancies or HCT recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Airway colonization in lung transplant recipients with cystic fibrosis is a risk factor following transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=see_link&amp;anchor=H6#H6\">",
"       \"Fungal infections following lung transplantation\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In liver transplant recipients, increasing immunosuppression, hemodialysis, and CMV infection are risks factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis most frequently occurs in the lungs or sinuses after inhalation of conidia, although, less commonly, disease can spread from the gastrointestinal tract, or result from direct inoculation into the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis most commonly involves the lungs (",
"    <a class=\"graphic graphic_picture graphicRef57220 \" href=\"mobipreview.htm?17/49/18202\">",
"     picture 1",
"    </a>",
"    ). Patients can present with a number of signs and symptoms: fever, chest pain, shortness of breath, cough,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemoptysis. The classic triad that has been described in neutropenic patients with pulmonary aspergillosis is fever, pleuritic chest pain, and hemoptysis. However, absence of this triad should not discourage consideration of this diagnosis in the patient with risk factors for disease since neutropenic patients frequently present with fever in the absence of localizing pulmonary symptoms. In such patients, lung imaging often reveals pulmonary nodules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H429431\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray is insensitive for detecting the earliest stages of pulmonary disease, but computed tomography (CT) scans typically demonstrate focal lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56195 \" href=\"mobipreview.htm?41/47/42738\">",
"     image 1",
"    </a>",
"    ). The type of radiographic abnormality is variable, depending upon the host and the type of disease: bronchopneumonia, angioinvasive aspergillosis, tracheobronchitis, or chronic necrotizing aspergillosis.",
"   </p>",
"   <p>",
"    Pulmonary aspergillosis typically manifests as single or multiple nodules with or without cavitation, patchy or segmental consolidation, or peribronchial infiltrates with or without tree-in-bud patterns. One relatively large review noted that small nodules (&lt;1 cm) were most common (20 of 46; 43 percent), followed by consolidation (12 of 46; 26 percent), large nodules (masses, 10 of 46; 21 percent), and peribronchial infiltrates (4 of 46; 9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/16\">",
"     16",
"    </a>",
"    ]. Another large study that included neutropenic and non-neutropenic patients showed that the more specific signs (nodules and cavitation) were infrequent, with principal radiographic findings including consolidation, ground-glass infiltrates, and pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings, as with disease manifestations, can be variable and largely depend upon the host. The radiographic progression of disease has been studied best in neutropenic patients, in whom the initial findings typically include nodules that have surrounding ground glass infiltrates (the halo sign), reflecting hemorrhage into the area surrounding the fungus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56195 \" href=\"mobipreview.htm?41/47/42738\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/18\">",
"     18",
"    </a>",
"    ]. These nodules typically enlarge, even during appropriate therapy, and may eventually cavitate, producing the air-crescent sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in one study it was noted that neutropenic patients more frequently presented with segmental areas of consolidation rather than demonstrating the classic nodule progression to cavitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70038 \" href=\"mobipreview.htm?41/33/42515\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/17\">",
"     17",
"    </a>",
"    ]. Similar findings were reported in a cohort of solid organ transplant recipients, with the majority of patients presenting with \"pulmonary pneumonia\" (focal infiltrates, 39 percent) or \"pulmonary nodular\" (21 percent) findings on CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/21\">",
"     21",
"    </a>",
"    ]. In a cohort of 139 children, the most common radiographic presentation was nodules (35 percent); few children developed cavitary disease (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study has indicated that there may be a role for CT pulmonary angiography for distinguishing between invasive mold infections and other causes of pulmonary infiltrates, by virtue of detection of angioinvasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/23\">",
"     23",
"    </a>",
"    ]. However, this study was small, did not evaluate patients with a heterogeneous group of underlying diseases, and the results have not been evaluated based on potential excessive risks associated with the use of IV contrast. Larger studies will be needed to define the role of CT pulmonary angiography for diagnosing invasive aspergillosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354412\">",
"    <span class=\"h2\">",
"     Tracheobronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus tracheobronchitis has been reported most commonly in lung transplant recipients, but has also been described in other types of hosts (eg, recipients of other solid organ transplants, patients with hematologic malignancies, patients with HIV infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=see_link&amp;anchor=H8#H8\">",
"     \"Fungal infections following lung transplantation\", section on 'Tracheobronchial aspergillosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35270?source=see_link\">",
"     \"Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients typically present with prominent dyspnea, cough, and wheezing; they occasionally expectorate intraluminal mucus plugs. Chest imaging may be normal or reveal areas of airway thickening, patchy infiltrates, consolidation, or centrilobular nodules.",
"   </p>",
"   <p>",
"    Different patterns of Aspergillus tracheobronchitis have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive bronchial aspergillosis, a condition in which thick mucus plugs filled with Aspergillus hyphae are found in the airways, with little mucosal inflammation or invasion",
"     </li>",
"     <li>",
"      Ulcerative tracheobronchitis, in which there is focal invasion of the tracheobronchial mucosa",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cartilage by fungal hyphae",
"     </li>",
"     <li>",
"      Pseudomembranous tracheobronchitis, which is characterized by extensive inflammation and invasion of the tracheobronchial tree with a pseudomembrane composed of necrotic debris and Aspergillus hyphae overlying the mucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lung transplant recipients can also develop aspergillosis of the bronchial stump. This complication results from infection of the suture material and its incidence can be reduced with the use of nylon monofilaments, rather than silk sutures. Patients complain of cough and may have hemoptysis.",
"   </p>",
"   <p>",
"    Tracheobronchial disease can also occur in other hosts, including those who have hematologic malignancies, hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/25\">",
"     25",
"    </a>",
"    ], and chronic obstructive pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic necrotizing and chronic cavitary pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have underlying chronic lung disease are at risk for indolent forms of pulmonary aspergillosis, characterized by cavities or infiltrates that may or may not demonstrate hyphal invasion of tissue on histopathology. Presumably, the slowly progressive nature of this infection is a function of the host immune response, which is enough to hold the organism in check, but not to eliminate it. Cough, weight loss, fatigue, and chest pain are common, and the chest x-ray shows a slowly progressive lesion, which can be better defined by CT scanning. However, interpretation of radiologic studies may be complicated by the presence of concomitant lung disease, since this is the setting in which chronic invasive aspergillosis usually occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58499421\">",
"    <span class=\"h2\">",
"     Disseminated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of angioinvasive disease, Aspergillus spp can disseminate beyond the respiratory tract to multiple different organs, including the skin, brain, eyes, liver, and kidneys. Disseminated infection is associated with a very poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354431\">",
"    <span class=\"h2\">",
"     Rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the paranasal sinuses, aspergillosis can present in an identical fashion to mucormycosis. However, rhinocerebral aspergillosis is usually seen in neutropenic patients, whereas mucormycosis more often occurs in those with diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inflammatory response to the infection may be blunted because of neutropenia, and findings may be subtle. Nevertheless, nasal congestion, fever, and pain in the face and around the eye are common presenting features. If the orbit becomes involved, additional symptoms may include blurred vision, proptosis, and chemosis. The infection can also extend locally into the vasculature and the brain, leading to cavernous sinus thrombosis and a variety of central nervous system (CNS) manifestations.",
"   </p>",
"   <p>",
"    Imaging findings may be subtle and can include focal soft tissue lesions, subtle focal bony erosions, focal enhancement of the sinus lining on magnetic resonance imaging or focal hypodense areas on computed tomography scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy is necessary to establish the diagnosis; multiple biopsies are sometimes necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link&amp;anchor=H1064486423#H1064486423\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Culture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=see_link&amp;anchor=H7#H7\">",
"     \"Fungal rhinosinusitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3038609\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS aspergillosis may occur in the setting of disseminated infection, as well as from local extension from the paranasal sinuses. Patients with CNS involvement with Aspergillus spp may present with seizures or focal neurological signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of the computed tomography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging findings associated with CNS aspergillosis, three patterns were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ring-enhancing lesions consistent with brain abscesses (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71228 \" href=\"mobipreview.htm?33/31/34289\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral cortical and subcortical infarction with or without superimposed hematomas (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50013 \" href=\"mobipreview.htm?21/18/21807\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mucosal thickening of a paranasal sinus with secondary intracranial dural enhancement consistent with direct extension from the sinuses (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66095 \" href=\"mobipreview.htm?29/0/29711\">",
"       image 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CNS infection is associated with a very poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H739446\">",
"    <span class=\"h3\">",
"     Outbreak of fungal meningitis and septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 United States outbreak of fungal meningitis and septic arthritis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18746?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354444\">",
"    <span class=\"h2\">",
"     Endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus endophthalmitis may be a presenting feature of disseminated aspergillosis, in which involvement of the deep structures of the eye results not only from hematogenous spread. In other patients, corneal infection or direct inoculation following trauma is the genesis of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients present with eye pain and visual changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive infection is characterized by destruction of multiple components of the eye. The outcome is usually poor with loss of useful vision in the affected eye, and a requirement for enucleation in some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/55/2937?source=see_link&amp;anchor=H634314692#H634314692\">",
"     \"Treatment of endophthalmitis due to molds\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354461\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus spp are second only to Candida spp as a cause of fungal endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/30\">",
"     30",
"    </a>",
"    ]. This infection occurs primarily in patients with prosthetic heart valves. In many patients, infection occurs at the time of surgery, with the fungus contaminating the surgical site. Patients may present at any time postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other patients at risk for the development of Aspergillus endocarditis include patients with indwelling central venous catheters and intravenous drug users.",
"   </p>",
"   <p>",
"    Patients typically present with fever and embolic phenomena. Blood cultures are rarely positive, even when a fungal isolator system is used. Microscopic examination of an embolus will reveal the typical hyphae suggestive of aspergillosis, but definitive microbiologic diagnosis depends upon culture of the organism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link&amp;anchor=H1064486423#H1064486423\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of Aspergillus endocarditis is poor. Even with combined medical and surgical therapy, the mortality rate has approached 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354468\">",
"    <span class=\"h2\">",
"     Cutaneous aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous aspergillosis can be either primary, occurring from direct inoculation, usually in the presence of trauma, or secondary, occurring from contiguous extension or blood-borne spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review noted that otherwise healthy hosts can develop cutaneous disease in surgical wounds by traumatic inoculation, or with exposure to high spore counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/32\">",
"     32",
"    </a>",
"    ]. While burn victims, neonates, and solid organ transplant recipients tend to develop primary cutaneous disease in the presence of prolonged local skin injury, patients with hematologic malignancies and hematopoietic cell transplant recipients more frequently develop disease due to contiguous or blood-borne invasion.",
"   </p>",
"   <p>",
"    Diagnosis can only be verified by skin biopsy, which should be taken from the center of the lesion and reach the subcutaneous fat in order to visualize hyphae invading blood vessels of the dermis and subcutis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link&amp;anchor=H1064486423#H1064486423\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625354475\">",
"    <span class=\"h2\">",
"     Gastrointestinal aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillosis can involve the gastrointestinal (GI) tract, causing focal invasion as a primary site of inoculation and presenting as typhlitis, colonic ulcers, abdominal pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Direct inoculation from the GI tract is likely, with risk factors including neutropenia, receipt of glucocorticoids, and mucosal breakdown (mucositis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250762355\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several fungi can cause invasive infections that are indistinguishable from invasive aspergillosis on clinical or radiographic grounds alone. Furthermore, the risk factors for invasive aspergillosis are similar to those for other invasive fungal infections. It is important to establish a microbiologic diagnosis since the treatment regimen depends upon the species isolated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fungi that can cause invasive pulmonary infections with clinical and radiographic features (eg, halo sign) that are similar to those caused by Aspergillus spp include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucorales (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fusarium spp (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6439?source=see_link\">",
"       \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Scedosporium apiospermum (Pseudoallescheria boydii) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41640?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Scedosporium infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Scedosporium prolificans (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41640?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Scedosporium infection\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The halo sign can also be seen with other fungal infections and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34616/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H429431\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mucormycosis can also cause rhinosinusitis with extension into the central nervous system that is clinically and radiographically similar to invasive aspergillosis. However, rhinocerebral aspergillosis is usually seen in neutropenic patients, whereas mucormycosis more often occurs in those with diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to Aspergillus spp, brain abscesses can be caused by a variety of fungi including the Mucorales, Fusarium spp, Scedosporium spp, and dematiaceous fungi. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43894?source=see_link\">",
"     \"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/23/12658?source=see_link\">",
"       \"Patient information: Invasive aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1016797\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"aspergillosis\" refers to illness due to allergy, airway or lung invasion, cutaneous infection, or extrapulmonary dissemination caused by species of Aspergillus. Aspergillus species are ubiquitous in nature, and inhalation of infectious conidia is a frequent event. Tissue invasion is uncommon and occurs most frequently in the setting of immunosuppression associated with therapy for hematologic malignancies, hematopoietic cell transplantation, or solid organ transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled conidia are met by the innate defenses provided by resident phagocytes, specifically, airway epithelial cells and alveolar macrophages. Macrophages secrete inflammatory mediators after recognition of key cell wall components (eg, beta-D-glucan) exposed after conidial germination into hyphal forms. These mediators result in neutrophil recruitment and the activation of cellular immunity, which are important in killing potentially invasive microbial forms (hyphae) and determining the extent and nature of the immune response. (See",
"      <a class=\"local\" href=\"#H625354394\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histopathologically, invasive aspergillosis is characterized by progression of the infection across tissue planes. One hallmark of infection is vascular invasion with subsequent infarction and tissue necrosis. (See",
"      <a class=\"local\" href=\"#H625354394\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most invasive infections are caused by members of the A. fumigatus species complex. In a report of 218 infections in the United States, 67 percent were caused by members of the A. fumigatus complex, followed by A. flavus (13 percent), A. niger (9 percent), and A. terreus (7 percent). (See",
"      <a class=\"local\" href=\"#H429415\">",
"       'Species prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Underlying conditions that compromise pulmonary and systemic immune responses to inhaled Aspergillus species serve as risk factors for invasive pulmonary aspergillosis. Classic risk factors for invasive aspergillosis include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe and prolonged neutropenia",
"     </li>",
"     <li>",
"      Receipt of high doses of glucocorticoids",
"     </li>",
"     <li>",
"      Other drugs or conditions that lead to chronically impaired cellular responses (eg, immunosuppressive regimens administered to treat autoimmune diseases and to prevent organ rejection, and AIDS) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive aspergillosis most commonly involves the lungs (",
"      <a class=\"graphic graphic_picture graphicRef57220 \" href=\"mobipreview.htm?17/49/18202\">",
"       picture 1",
"      </a>",
"      ). Disease can present with a number of signs and symptoms: fever, chest pain, shortness of breath, cough,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemoptysis. However, absence of symptoms should not discourage consideration of this diagnosis in the patient who has risk factors for disease since neutropenic patients frequently present with fever in the absence of localizing pulmonary symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulmonary aspergillosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary aspergillosis typically manifests as single or multiple nodules with or without cavitation, patchy or segmental consolidation, or peribronchial infiltrates, with or without tree-in-bud patterns. The radiographic progression of disease has been studied best in neutropenic patients in whom the initial findings typically include nodules that have surrounding ground glass infiltrates (the halo sign), reflecting hemorrhage into the area surrounding the fungus (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56195 \" href=\"mobipreview.htm?41/47/42738\">",
"       image 1",
"      </a>",
"      ). These nodules typically enlarge, even during appropriate therapy, and may eventually cavitate, producing the air-crescent sign. Other fungal infections and Pseudomonas aeruginosa can show similar radiographic findings as invasive aspergillosis. (See",
"      <a class=\"local\" href=\"#H429431\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H250762355\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of angioinvasive disease, Aspergillus spp can disseminate beyond the respiratory tract to multiple different organs, including the skin, brain, eyes, liver, and kidneys. Disseminated infection is associated with a very poor prognosis. (See",
"      <a class=\"local\" href=\"#H58499421\">",
"       'Disseminated infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other manifestations of invasive aspergillosis include tracheobronchitis, rhinosinusitis, brain abscess, endophthalmitis, endocarditis, and gastrointestinal disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of invasive pulmonary aspergillosis includes other angioinvasive fungal infections, such as mucormycosis, fusariosis, and scedosporiosis. (See",
"      <a class=\"local\" href=\"#H250762355\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/1\">",
"      Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/2\">",
"      Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 2010; 150:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/3\">",
"      Balajee SA, Marr KA. Phenotypic and genotypic identification of human pathogenic aspergilli. Future Microbiol 2006; 1:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/4\">",
"      Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/5\">",
"      Lambourne J, Agranoff D, Herbrecht R, et al. Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2009; 49:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/6\">",
"      Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/7\">",
"      Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/8\">",
"      Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/9\">",
"      Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/10\">",
"      Zaas AK, Liao G, Chien JW, et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008; 4:e1000101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/11\">",
"      Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/12\">",
"      Chai LY, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human &beta;-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis 2011; 203:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/13\">",
"      Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007; 26:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/14\">",
"      Fort&uacute;n J, Mart&iacute;n-D&aacute;vila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/15\">",
"      Rosenhagen M, Feldhues R, Schmidt J, et al. A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009; 37:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/16\">",
"      Horger M, Hebart H, Einsele H, et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome? Eur J Radiol 2005; 55:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/17\">",
"      Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/18\">",
"      Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/19\">",
"      Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/20\">",
"      Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/21\">",
"      Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/22\">",
"      Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121:e1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/23\">",
"      Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012; 54:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/24\">",
"      Fern&aacute;ndez-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/25\">",
"      van Assen S, Bootsma GP, Verweij PE, et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/26\">",
"      Sivak-Callcott JA, Livesley N, Nugent RA, et al. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthalmol 2004; 88:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/27\">",
"      Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/28\">",
"      Levin LA, Avery R, Shore JW, et al. The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol 1996; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/29\">",
"      Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/30\">",
"      Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/31\">",
"      El-Hamamsy I, D&uuml;rrleman N, Stevens LM, et al. Aspergillus endocarditis after cardiac surgery. Ann Thorac Surg 2005; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/32\">",
"      van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998; 36:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/33\">",
"      Eggimann P, Chevrolet JC, Starobinski M, et al. Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. Infection 2006; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34616/abstract/34\">",
"      Gonz&aacute;lez-Vicent M, D&iacute;az MA, Colmenero I, et al. Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transpl Infect Dis 2008; 10:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2454 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34616=[""].join("\n");
var outline_f33_51_34616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1016797\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H625354394\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIAL EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H429408\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H429415\">",
"      Species prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H429431\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625354412\">",
"      Tracheobronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic necrotizing and chronic cavitary pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58499421\">",
"      Disseminated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625354431\">",
"      Rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3038609\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H739446\">",
"      - Outbreak of fungal meningitis and septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625354444\">",
"      Endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625354461\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625354468\">",
"      Cutaneous aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625354475\">",
"      Gastrointestinal aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H250762355\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1016797\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2454|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/47/42738\" title=\"diagnostic image 1\">",
"      CT pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/33/42515\" title=\"diagnostic image 2\">",
"      Aspergillus bronchiolitis and bronchopneumonia HRCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/31/34289\" title=\"diagnostic image 3\">",
"      Aspergillus brain abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/18/21807\" title=\"diagnostic image 4\">",
"      Aspergillus cortical infarct with hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/0/29711\" title=\"diagnostic image 5\">",
"      Aspergillus sinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2454|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/49/18202\" title=\"picture 1\">",
"      Aspergillus bronchopneumonia histopathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43894?source=related_link\">",
"      Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11178?source=related_link\">",
"      Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41640?source=related_link\">",
"      Epidemiology and clinical manifestations of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35270?source=related_link\">",
"      Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18746?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/23/12658?source=related_link\">",
"      Patient information: Invasive aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/55/2937?source=related_link\">",
"      Treatment of endophthalmitis due to molds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_51_34617="Median weight for length";
var content_f33_51_34617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determination of median weight for length for a boy who weighs 9 kg and is 78 cm long",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 547px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To determine the median weight for length, plot the child on the weight-for-length curve (Point A). Draw a vertical line to the 50th percentile curve (Point B). Draw a horizontal line to the weight scale (Point C). In the above example, the child weighs 9 kg and has a length of 78 cm. The median weight for a length of 78 cm is 10.4 kg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). Available at www.cdc.gov/growthcharts.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34617=[""].join("\n");
var outline_f33_51_34617=null;
var title_f33_51_34618="Procedural sedation in adults";
var content_f33_51_34618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Procedural sedation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34618/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34618/contributors\">",
"     Robert L Frank, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34618/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/51/34618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34618/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/51/34618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice of acute care medicine often requires the performance of procedures that can cause pain and anxiety. Procedural sedation reduces the discomfort, apprehension, and potential unpleasant memories associated with such procedures and facilitates performance of the procedure.",
"   </p>",
"   <p>",
"    The practice of procedural sedation in adults, including monitoring and medications, will be reviewed here. Procedural sedation in children and the sedation required for lengthier procedures, such as colonoscopy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedural sedation involves the use of short-acting analgesic and sedative medications to enable clinicians to perform procedures effectively, while monitoring the patient closely for potential adverse effects. This process was previously (and inappropriately) termed \"conscious sedation\", but because effective sedation often alters consciousness the preferred term is now \"procedural sedation and analgesia\" (PSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The practice of providing sedation, once primarily the domain of anesthesia practitioners, is now routinely performed by other specialists, such as emergency clinicians, critical care specialists, and various nurse specialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognizing that PSA exists along a spectrum, the Joint Commission on Accreditation of Healthcare Organizations in the United States has attempted to define the levels of sedation, which range from minimal sedation to general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Common terms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analgesia &ndash; Relief of pain without intentionally producing a sedated state. Altered mental status may occur as a secondary effect of medications administered for analgesia.",
"     </li>",
"     <li>",
"      Minimal sedation &ndash; The patient responds normally to verbal commands. Cognitive function and coordination may be impaired, but ventilatory and cardiovascular functions are unaffected.",
"     </li>",
"     <li>",
"      Moderate sedation and analgesia &ndash; The patient responds purposefully to verbal commands alone or when accompanied by light touch. Protective airway reflexes and adequate ventilation are maintained without intervention. Cardiovascular function remains stable.",
"     </li>",
"     <li>",
"      Deep sedation and analgesia &ndash; The patient cannot be easily aroused, but responds purposefully to noxious stimulation. Assistance may be needed to ensure the airway is protected and adequate ventilation maintained. Cardiovascular function is usually stable.",
"     </li>",
"     <li>",
"      General anesthesia &ndash; The patient cannot be aroused and often requires assistance to protect the airway and maintain ventilation. Cardiovascular function may be impaired.",
"     </li>",
"     <li>",
"      Dissociative sedation &ndash; Dissociative sedation is a trance-like cataleptic state in which the patient experiences profound analgesia and amnesia, but retains airway protective reflexes, spontaneous respirations, and cardiopulmonary stability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      is the pharmacologic agent used for procedural sedation that produces this state. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Ketamine'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sedation exists on a continuum, and it is difficult to divide it into discrete clinical stages, the definitions above notwithstanding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/5\">",
"     5",
"    </a>",
"    ]. Moreover, many sedatives can cause rapid changes in the depth of sedation. Dissociative sedation stands apart from the continuum of sedation due to its unique characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute indications for the performance of PSA. PSA may be used for any procedure in which a patient's pain or anxiety may be excessive and may impede performance. PSA is often useful for procedures where deep relaxation facilitates performance (eg, closed reduction of a dislocated joint). Common procedures in which PSA may be beneficial include electrical cardioversion, closed joint reduction, complicated laceration repair, abscess incision and drainage, and lumbar puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to PSA. Relative contraindications may include: older age, significant medical comorbidities, and signs of a difficult airway. Whether the patient recently ate should be considered before performing PSA, although this does not appear to have a major impact on aspiration risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Aspiration risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several factors must be considered before proceeding with PSA. First, the clinician and the patient must agree that the potential benefit of PSA outweighs the risks. Risk depends upon the patient and the procedure.",
"   </p>",
"   <p>",
"    There is no specific age above which PSA may not be performed. Nevertheless, the elderly have higher rates of adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/9\">",
"     9",
"    </a>",
"    ]. This may be due to an increased sensitivity to sedative drugs, medication interactions, and higher peak serum levels of administered drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with major comorbid medical conditions are at increased risk for adverse events with PSA. This correlates with an ASA physical status classification of Class III or greater (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"mobipreview.htm?8/33/8733\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Important comorbidities are those that increase patient susceptibility to the cardiorespiratory depressant effects of sedatives. They include heart failure, chronic obstructive pulmonary disease, neuromuscular disease, dehydration, and anemia. Unfortunately, there is no evidence that alternative approaches (eg, monitored anesthesia care or general anesthesia in the operating room) are safer for patients at increased risk from PSA.",
"   </p>",
"   <p>",
"    To reduce the risk of adverse events in the elderly and patients with major comorbid disease, we suggest a more conservative approach to PSA medications, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Giving a lower starting dose",
"     </li>",
"     <li>",
"      Using slower rates of administration",
"     </li>",
"     <li>",
"      Repeated dosing of medications at less frequent intervals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PSA is relatively contraindicated in patients who are likely to be difficult to ventilate or oxygenate should respiratory difficulties arise while the patient is sedated. Alternatives to PSA may be preferable if signs suggesting a difficult airway are identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No data clearly demonstrate that a longer duration of PSA correlates with an increase in adverse outcomes. Nevertheless, common sense suggests that it is preferable to sedate patients for the shortest period necessary to perform the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Aspiration risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of gastric contents during anesthesia or PSA is a rare, though much feared complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Patients undergoing emergency procedures requiring sedation are thought to be at increased risk of aspiration because their stomachs are often full, and the procedure cannot be delayed. Aspiration frequently does not cause harm. However, aspirated gastric contents above a critical volume and acidity can cause severe respiratory and systemic consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/13\">",
"     13",
"    </a>",
"    ]. The importance of fasting for preventing aspiration during PSA remains unclear.",
"   </p>",
"   <p>",
"    Guidelines to reduce aspiration risk were put forth in a consensus statement by the American Society of Anesthesiologists (ASA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3\">",
"     3",
"    </a>",
"    ]. These guidelines are based upon expert opinion and to a lesser extent extrapolated from general anesthesia data, in which aspiration with serious consequences is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. The ASA guidelines recommend that patients undergoing PSA for \"elective procedures\" fast according to the standards used for general anesthesia. This requires that patients not eat or drink for two hours after drinking clear liquids and six hours after ingesting solid foods or cow's milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3\">",
"     3",
"    </a>",
"    ]. If these standards cannot be met, the guidelines recommend that the clinician consider delaying the procedure, reducing the level of sedation, or protecting the airway with endotracheal intubation.",
"   </p>",
"   <p>",
"    Implementing these guidelines in the emergency department (ED) presents several problems. First, it is rare that patients requiring emergent PSA meet these fasting criteria. Second, emergent procedures cannot be delayed. Finally, although fasting to reduce the risk of aspiration during PSA or elective surgery makes intuitive sense, there is little evidence to support this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to one review, patients who fast for two hours have the same gastric volume and pH as those who fast for longer periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/13\">",
"     13",
"    </a>",
"    ]. Furthermore, there is no clear evidence that a relationship exists among fasting time, gastric volume, gastric pH, depth of sedation, and the likelihood of aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/6,12,16,18-20\">",
"     6,12,16,18-20",
"    </a>",
"    ]. Clinically significant aspiration during emergency department PSA appears to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, endotracheal intubation may not protect the patient from aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/14,18,19,21-23\">",
"     14,18,19,21-23",
"    </a>",
"    ]. Aspiration can occur despite the presence of an endotracheal tube, while the airway manipulation involved in performing intubation appears to increase the risk of aspiration.",
"   </p>",
"   <p>",
"    In light of the available literature, the American College of Emergency Physicians policy statement on PSA states: \"Recent food intake is not a contraindication for administering procedural sedation and analgesia, but should be considered in choosing the timing and target of sedation\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24\">",
"     24",
"    </a>",
"    ]. We concur and suggest the following approach to reducing aspiration risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carefully consider the risks and benefits of performing the procedure emergently. Although there is no proof that longer fasting times reduce aspiration risk, it is reasonable to wait if the patient's stomach is full and the procedure is not a true emergency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/25\">",
"       25",
"      </a>",
"      ]. This is particularly true when a potentially difficult airway or an increased risk for aspiration exists, such as with the following circumstances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/18\">",
"       18",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conditions predisposing to esophageal reflux (eg, bowel obstruction, hiatal hernia)",
"     </li>",
"     <li>",
"      Extremes of age (&lt;6 months or &gt;70 years old)",
"     </li>",
"     <li>",
"      Severe systemic disease (ASA class III or greater)",
"     </li>",
"     <li>",
"      Other concerning conditions (eg, depressed mental status)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid deep sedation. No evidence clearly demonstrates that deeper levels of sedation increase the risk of aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/18\">",
"       18",
"      </a>",
"      ]. Nevertheless, lighter sedation may permit the patient to maintain protective airway reflexes, which reduces risk.",
"     </li>",
"     <li>",
"      We do not suggest administration of pre-procedural antacids or motility agents to reduce aspiration risk. These medications have not been shown to reduce such risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases it may be best to perform the procedure under general anesthesia in the operating room, although this approach has not been proven to reduce the risk of aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PERFORMING PROCEDURAL SEDATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before performing PSA, the clinician must discuss the risks, benefits, and alternatives of the procedure and the planned sedation with the patient and answer any questions. A printed informed consent form may be used. Implied consent is acceptable in some cases where the patient is unable to provide explicit consent due to severe pain or altered mental status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prerequisites and personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although previously the domain of anesthesia practitioners, PSA is performed safely by other clinicians, including emergency and critical care physicians and nurse specialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/26\">",
"     26",
"    </a>",
"    ]. Clinicians providing PSA should have in-depth knowledge of the relevant drugs, including their mechanism of action, doses, side effects, and reversal agents. Such clinicians must also be well versed in advanced cardiovascular life support, including airway management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The number of clinicians needed to perform PSA and the procedure safely may vary according to the patient and the procedure. In most cases, one clinician performs the procedure while another (usually a nurse) administers the sedative agents and monitors and records the patient's vital signs and clinical status. Whenever possible, we suggest that this minimum standard be met.",
"   </p>",
"   <p>",
"    It remains controversial whether an additional clinician, separate from the clinician performing the procedure, who is skilled in deep sedation administration and airway management should be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. Guidelines from the American Society of Anesthesiologists (ASA) call for someone with \"advanced life support skills\" to be immediately available (within five minutes) for PSA and present in the procedure room whenever deep sedation is being performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3\">",
"     3",
"    </a>",
"    ]. Large case series of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    sedation administered by nurses for ambulatory procedures demonstrate that serious adverse events can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/27\">",
"     27",
"    </a>",
"    ]. However, one prospective observational study of over 1000 procedural sedations found that PSA performed by a single emergency clinician (EP) had comparably low complication and high success rates when compared with PSA performed with both an EP and a nurse present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All equipment necessary to perform the procedure and manage the airway should be available at the bedside during the performance of PSA. Such equipment includes suction to manage vomiting or oral secretions, airway adjuncts, such as a bag-valve mask and oral and nasal airways, and equipment to perform endotracheal intubation. Intravenous access should be established. Resuscitation medications, including advanced cardiac life support medications and reversal agents (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    ) should be available. Appropriate monitors should be in place. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring and preoxygenation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring and preoxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper monitoring during the performance of PSA is crucial. The patient's blood pressure, heart rate, and respiratory rate should be measured at frequent, regular intervals; the oxygen saturation (SpO2), end-tidal carbon dioxide level (EtCO2), and cardiac rhythm should be monitored continuously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient's response to medications and the procedure must also be closely monitored during PSA. The patient's level of alertness, depth of respiration, and response to painful stimuli (eg, fracture reduction) are all important factors in determining subsequent medication doses. Sedation scales, such as the Richmond Agitation Sedation Scale and the Ramsay Score, have not been adequately studied in the setting of PSA. They may be more useful in determining the appropriate titration of sedatives during long-term procedures (eg, mechanical ventilation).",
"   </p>",
"   <p>",
"    Supplemental oxygen is often recommended during PSA to maintain oxygen reserves and prevent hypoxemia caused by hypoventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there is little evidence to show that this is beneficial and some researchers question the practice.",
"   </p>",
"   <p>",
"    The best evidence supporting the use of oxygen is a double blind, randomized trial of adults undergoing PSA with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    in which episodes of hypoxia (SpO2 &lt;93 percent) lasting longer than 15 seconds occurred significantly more often (41 percent) among the 58 patients given compressed air by face mask compared to the 59 patients given high flow oxygen (19 percent) using the same delivery system (difference 23 percent; 95 percent CI 6 to 38 percent). [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the clinical significance of such transient episodes of hypoxia remains debatable.",
"   </p>",
"   <p>",
"    Several observational studies have found that supplemental oxygen at lower concentrations does not reliably prevent hypoxemia during PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], and delays the detection of respiratory depression in patients without EtCO2 monitors, since SpO2 levels may not fall until a prolonged period of hypoventilation or apnea has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Nevertheless, we suggest that high flow oxygen by face mask be given to patients undergoing PSA because it may reduce the likelihood of hypoxic episodes, particularly with prolonged procedures, is easy to perform, and is highly unlikely to cause harm.",
"   </p>",
"   <p>",
"    However, among patients not provided with supplemental oxygen, respiratory difficulty during PSA can manifest earlier as hypoxia, as detected by pulse oximetry, rather than as hypoventilation, as determined by EtCO2 monitors, according to a small nested randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/34\">",
"     34",
"    </a>",
"    ]. Therefore, close attention to pulse oximetry readings remains critical in patients&rsquo; breathing room air during PSA.",
"   </p>",
"   <p>",
"    We recommend pulse oximetry and EtCO2 monitoring for all patients undergoing PSA. EtCO2 measurements correlate closely with arterial CO2 and provide an early sign of hypoventilation or apnea, especially if supplemental oxygen is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/32,33,35-37\">",
"     32,33,35-37",
"    </a>",
"    ]. EtCO2 is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While intuitively it makes sense that early detection of hypoxemia and hypoventilation is beneficial, there is no data to suggest that brief episodes of either have a negative impact on patient outcome, especially if recognized quickly and treated appropriately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24,38\">",
"     24,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bispectral analysis monitoring (BIS), a technology developed to monitor the level of general anesthesia, does not appear to be useful for monitoring the depth of procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. BIS measurements do not appear to correlate well with clinical sedation and have poor reproducibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Considerations in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications of procedural sedation guidelines recommended for pregnant women include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preprocedural administration of medication to improve gastroesophageal sphincter tone and reduce gastric volume (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ) and decrease stomach acidity (eg, H2 antagonists, sodium citrate) may reduce the risk of vomiting and aspiration and is unlikely to cause harm. Aspiration risk is discussed separately. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Aspiration risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preprocedural hydration and left lateral displacement of the uterus (in the late second and the third trimester) helps to reduce the risk of hypotension, uteroplacental insufficiency, and resultant fetal hypoxemia. Fetal monitoring is not required, but should be considered for women in the third trimester. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link\">",
"       \"Antepartum fetal heart rate assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oxygen by face-mask is administered because of the risk of sedation-related maternal desaturation (primarily due to decreased functional residual capacity). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=see_link\">",
"       \"Respiratory tract changes during pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link\">",
"       \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications attributable to PSA rarely occur. Significant respiratory compromise, the most concerning potential complication, develops in less than 1 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/42\">",
"     42",
"    </a>",
"    ]. Adverse outcomes may include respiratory depression with hypoxia or hypercarbia, cardiovascular instability, vomiting and aspiration, emergence reactions, and inadequate sedation preventing completion of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies of pediatric patients have found that PSA is safe, with no deaths reported and few serious consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/27,43-45\">",
"     27,43-45",
"    </a>",
"    ]. One observational case series of 640 patients undergoing PSA reported a 15 percent combined adverse event rate (adverse event and failure to perform procedure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/9\">",
"     9",
"    </a>",
"    ]. In this study, factors associated with adverse events included older age, the presence of multiple medical conditions (ie, higher ASA class), and the performance of esophagoscopy or cardioversion.",
"   </p>",
"   <p>",
"    Many complications can be prevented through appropriate selection of patients, proper use of sedative medication, and careful monitoring of sedation. Particular attention should be paid to patients in whom oxygenation and ventilation may be difficult, should the need for airway management arise. Such patients may not be appropriate candidates for PSA. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Contraindications and precautions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nearly all of the sedative agents used for PSA can cause dose-dependent respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10\">",
"     10",
"    </a>",
"    ]. Therefore, respiratory complications are the most common adverse events. Oxygen desaturation develops in up to 11 percent of adults who receive PSA with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    and are given supplemental oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ]. Rates are slightly higher if supplemental oxygen is not used. Oxygen desaturation can be minimized by cautious, unhurried medication administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoventilation and apnea may occur but are usually short-lived due to the brief duration of the drugs used for PSA. These complications nearly always resolve with patient stimulation, supplemental oxygen, positioning of the airway, or brief ventilatory support using a bag-valve mask. Treatment with the reversal agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    may be necessary with more severe or prolonged respiratory depression during PSA using opioids or benzodiazepines. The use of naloxone and flumazenil are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link&amp;anchor=H14#H14\">",
"     \"Opioid intoxication in adults\", section on 'Basic measures and antidotal therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"     \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant hypotension and bradycardia seldom occur, but may develop in patients with significant cardiac morbidity and those taking cardiodepressant medications (eg, beta blockers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10,42,46,47\">",
"     10,42,46,47",
"    </a>",
"    ]. The problems are usually transient and resolve without intervention. Hemodynamically neutral sedatives (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    ) may be preferable for patients at risk from changes in blood pressure or heart rate.",
"   </p>",
"   <p>",
"    Nausea and vomiting occur in about 5 percent of patients undergoing PSA, although rates may be higher when opioids are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Antiemetics may be used as needed. There is little evidence about the prophylactic use of antiemetics or which agent is preferable. In one randomized trial involving PSA with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , 16 of 127 children managed without antiemetics experienced post-procedural vomiting versus 6 of 128 children pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    , a 7.9 percent reduction in absolute risk (95% CI 1.1-14.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedural sedation and analgesia (PSA) typically involves the intravenous (IV) administration of sedative or dissociative agents, sometimes in combination with short-acting opioids (",
"    <a class=\"graphic graphic_table graphicRef52744 \" href=\"mobipreview.htm?8/14/8429\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24\">",
"     24",
"    </a>",
"    ]. Ideal drugs for PSA have a rapid onset and short duration of action, maintain hemodynamic stability, and do not cause major side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/2\">",
"     2",
"    </a>",
"    ]. Several medications are commonly used and no single drug is ideal for all situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is a phenol derivative that has been shown to provide effective PSA for emergent procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/2,53\">",
"     2,53",
"    </a>",
"    ]. Propofol is highly lipophilic and therefore crosses the blood-brain barrier rapidly. The drug takes effect within approximately 40 seconds, and its duration of action is approximately six minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12,53\">",
"     12,53",
"    </a>",
"    ]. Propofol acts as a sedative and amnestic, but provides no analgesia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    can induce deep sedation rapidly and must be given with careful attention to dosing and monitoring. For PSA in adults, propofol is given by slow injection in an initial loading dose of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, followed by doses of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every three to five minutes as necessary until the appropriate level of sedation is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ]. One reasonable approach to administration is to give 20 mg every 10 seconds (eg, a 50 mg dose would be given over 25 seconds), although there is no direct evidence demonstrating improved efficacy or safety using this regimen. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring and preoxygenation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    appear to be unchanged in patients with impaired kidney or liver function. However, plasma levels appear to be increased in elder patients, which can lead to prolonged sedation and more pronounced cardiorespiratory depression. Patients over 55 are particularly sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ]. The manufacturer recommends that doses in elders be reduced by 20 percent and that the drug be given more slowly (over three to five minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/54\">",
"     54",
"    </a>",
"    ]. Reductions from 20 to 60 percent of the dose used in a healthy young adult are reasonable (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Elderly patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    formulation contains egg lecithin and soybean oil, and therefore is contraindicated in patients with a sensitivity to either of these substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential side effects include hypotension (due to myocardial depression) and respiratory depression. These side effects generally resolve quickly and uneventfully because of the brief duration of action. However, hypotension can produce complications in patients with severe medical problems (eg, sepsis, cardiac dysfunction) or hypovolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory depression usually manifests as a mild oxygen desaturation. Coadministration with other sedatives or analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) can exacerbate respiratory problems. Episodes of hypoxia are generally uneventful and successfully treated with supplemental oxygen and patient stimulation, and less commonly require short periods of assisted ventilation with a bag-valve mask. There are no reports of endotracheal intubation due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    -induced respiratory depression during PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    provides",
"    <strong>",
"     no",
"    </strong>",
"    analgesia and can cause pain during injection through an intravenous catheter. According to a systematic review of 177 randomized controlled trials involving 25,260 adult patients, the following measures are significantly effective at reducing pain caused by propofol injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injecting into an antecubital vein rather than a hand vein (relative risk [RR] 0.14; 95% CI 0.07-0.30)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      pretreatment while occluding the vein (RR 0.29; 95% CI 0.22-0.38)",
"     </li>",
"     <li>",
"      Pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      admixture (RR 0.40; 95% CI 0.33-0.48)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      pretreatment without vein occlusion (RR 0.47; 95% CI 0.40-0.56)",
"     </li>",
"     <li>",
"      Opioid pretreatment (RR 0.49; 95% CI 0.41-0.59)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      pretreatment (RR 0.52; 95% CI 0.46-0.57)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain during injection can also be reduced by using larger catheters placed in larger veins.",
"   </p>",
"   <p>",
"    Pretreatment with any of several analgesics can reduce the pain caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . One effective approach is to place a tourniquet on the arm proximal to the injection site and then give 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    IV 30 to 120 seconds before propofol is injected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach is pretreatment with short-acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ). Unfortunately, the addition of opioids increases the likelihood of respiratory complications. As an example, fentanyl at a dose of 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    increases the risk of respiratory depression. To reduce this risk, smaller doses of fentanyl should be used. The best dose to provide adequate analgesia with minimal respiratory risk has yet to be identified. We suggest that no single dose of fentanyl exceed 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    when given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and that the total amount of fentanyl be kept to the minimum required for effective analgesia.",
"   </p>",
"   <p>",
"    It may not be necessary to combine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    with a short-acting opioid if the patient's pain is adequately treated prior to the procedure. This approach is supported by an unblinded randomized trial in which patients given PSA consisting of propofol alone had pain levels identical to those treated with both propofol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/57\">",
"     57",
"    </a>",
"    ]. For both treatment groups, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    was given at least 20 minutes prior to the procedure to all patients experiencing pain until their symptoms were adequately relieved. Of note, patients given both alfentanil and propofol required stimulation to induce respiration more often than those given only propofol.",
"   </p>",
"   <p>",
"    Another alternative to pretreatment with short-acting opioids is to use sub-dissociative doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    (0.3",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    Ketamine appears to provide comparable analgesia with less risk of respiratory depression. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Ketamine versus short-acting opioids for analgesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In some instances, patients experience little or no pain before or after a procedure (eg, lumbar puncture, cardioversion) and little if any analgesia may be necessary to supplement",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . In addition, some procedures lead to a substantial reduction in pain (eg, dislocation reduction), decreasing the need for analgesics as part of PSA.",
"   </p>",
"   <p>",
"    Multiple randomized trials and prospective observational studies have found",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    to be safe and effective for PSA in the emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ]. Even in the contentious area of nurse-administered propofol sedation, where typically the only physician present is performing the procedure (eg, outpatient endoscopy), there is a large body of evidence documenting the safety and efficacy of propofol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the evidence above, not all clinicians who are qualified and wish to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    for PSA are allowed to do so. Reasons for this are complex and beyond the scope of this discussion, but may include misunderstandings about patient safety as well as political and economic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The manufacturer's label states: \"only those persons trained in the administration of general anesthesia should administer the drug,\" and goes on to state: \"only those persons not involved in the conduct of the",
"    <span class=\"nowrap\">",
"     surgical/diagnostic",
"    </span>",
"    procedure should administer the drug\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/62\">",
"     62",
"    </a>",
"    ]. In the United States, these statements have led some nursing organizations to question whether nurses other than certified registered nurse anesthetists should administer propofol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Etomidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    , an imidazole derivative, is a sedative that is commonly used for PSA. The use of etomidate for rapid sequence intubation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For PSA in adults,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    is given IV over 30 to 60 seconds in doses of 0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    less than the dose used for rapid sequence intubation. It can be redosed approximately every three to five minutes as needed. The onset of action of etomidate is almost immediate and its duration of effect is 5 to 15 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    can have more profound and prolonged effects in the elderly and patients with renal or hepatic dysfunction. In such patients, doses in the lower dosing range should be used. An important benefit of etomidate is that it maintains cardiovascular stability.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    has no analgesic properties and often requires the coadministration of a short-acting opioid, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , which increases the risk of respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/64\">",
"     64",
"    </a>",
"    ]. To reduce this risk, smaller doses of fentanyl should be used. The best dose to provide adequate analgesia with minimal respiratory risk has yet to be identified. We suggest that no single dose of fentanyl exceed 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    when given with etomidate and that the total amount of fentanyl be kept to a minimum.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    causes pain during injection into peripheral veins. Strategies similar to those used for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    can be used to reduce such pain. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Propofol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several randomized trials and prospective observational studies have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    is an effective sedation agent for PSA and does not cause major complications (eg, respiratory depression requiring endotracheal intubation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63,65-67\">",
"     63,65-67",
"    </a>",
"    ]. However, side effects, particularly myoclonus, occur with regularity and procedure success rates may be lower when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Propofol versus etomidate'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    include myoclonus, respiratory depression, adrenal suppression, and nausea and vomiting. Myoclonus is the most frequently reported side effect. It is thought to be related to subcortical disinhibition and has been reported in up to 80 percent of patients who receive etomidate for PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. The degree of myoclonus may be dose dependent and ranges from mild and transient to severe enough to prevent completion of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports of severe myoclonus associated with PSA are rare. In such cases, we suggest immediate airway support and treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , 1 to 2 mg IV approximately every 60 seconds until myoclonus abates. Alternative benzodiazepines may be used if midazolam is unavailable.",
"   </p>",
"   <p>",
"    Strategies to prevent myoclonus vary and there is insufficient evidence to support any one approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      According to one small randomized trial, a pretreatment dose of 0.03 to 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      given 50 seconds before the PSA dose reduces myoclonus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another small randomized trial in patients undergoing cardioversion found that a small dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      (0.015",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      given at the same time as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      prevents myoclonus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      administered 90 seconds prior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      was found to reduce myoclonus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to a systematic review of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for PSA, respiratory depression occurs in approximately 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/65\">",
"     65",
"    </a>",
"    ]. In this review, respiratory depression was defined as a fall in oxygen saturation below 90 percent or apnea. No serious complications occurred as a result and respiratory depression resolved quickly without major interventions in the great majority of cases. Nevertheless, clinicians must be prepared to support the patient's airway and breathing in the event of respiratory compromise, as is true whenever PSA is performed.",
"   </p>",
"   <p>",
"    When given by continuous infusion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    causes adrenal insufficiency. In addition, reductions in plasma cortisol concentrations have been reported in patients receiving a single induction dose of etomidate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. However, the clinical significance of transient reductions in cortisol in patients undergoing PSA with etomidate remains unclear. Most such patients are relatively healthy and receive a single sedating dose. In such patients, complications related to adrenal suppression have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Benzodiazepines (midazolam)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are commonly used for minimal sedation (anxiolysis), but less often for deeper sedation due to the superior effectiveness of the ultrashort-acting agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    . Benzodiazepines produce anxiolysis and amnesia, but have no analgesic properties.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    is the benzodiazepine used most often for PSA. Because it is lipophilic, midazolam penetrates the blood-brain barrier quickly. Midazolam can be used alone for anxiolysis or in combination with short-acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) for deeper levels of sedation and analgesia. Its time of onset is two to five minutes, and its duration of action is 30 to 60 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    is usually given IV over one to two minutes in doses of 0.02 to 0.03",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Often in adults, midazolam is given 0.5 or 1 mg at a time and titrated to effect. No single dose should exceed 2.5 mg. Repeat doses may be given every two to five minutes as necessary.",
"   </p>",
"   <p>",
"    With repeated doses,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    accumulates in adipose tissue, which can significantly prolong sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/75\">",
"     75",
"    </a>",
"    ]. The elderly, obese, and those with renal or hepatic disease are at greater risk of prolonged sedation. In such patients, the use of lower doses, longer dosing intervals, and smaller total amounts reduces risk.",
"   </p>",
"   <p>",
"    The amount of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    necessary for adequate sedation varies based upon many factors, including patient size and age, medication tolerance, comorbidities, and the duration of the procedure. In most cases, PSA can be performed using no more than 5 mg of midazolam. For longer procedures likely to require multiple doses of a sedative, ultrashort-acting agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ) may be preferable. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Propofol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Compared with ultrashort-acting agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    has a longer duration of action that makes it better suited for anxiolysis than for PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/69\">",
"     69",
"    </a>",
"    ]. Midazolam can cause respiratory depression in high doses or when given concomitantly with other sedatives or narcotics. For anxiolysis, a single dose of 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (approximately 1 to 2 mg) is usually sufficient.",
"   </p>",
"   <p>",
"    Other benzodiazepines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , are less suited for PSA due to their relatively prolonged onset and duration of action. They also have more side effects and inferior amnestic properties compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Short-acting opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are often given alone or in combination with sedatives for PSA. Short-acting agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    , are used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is a synthetic opioid that was frequently used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    to provide analgesia during PSA before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    became widely available. It has 75 to 125 times the potency of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , a rapid onset of action (two to three minutes), and a short duration of effect (30 to 60 minutes), but has no amnestic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is usually given by slow IV push in doses of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    every two minutes until an appropriate level of sedation and analgesia is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/76\">",
"     76",
"    </a>",
"    ]. The maximum total dose is generally 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    or approximately 250 mcg, but higher doses may be needed in some instances.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    rarely causes hypotension and does not stimulate histamine release. Its primary side effect is respiratory depression, which is potentiated by the coadministration of sedatives. Patients with renal or hepatic disease and the elderly can experience more prolonged or profound effects. In such patients, the use of lower doses, longer dosing intervals, and smaller total amounts reduces risk.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     Remifentanil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    are opioids similar in structure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    with a rapid onset and duration of action of approximately five minutes. The potency of remifentanil and fentanyl are comparable, but alfentanil is one-fifth to one-tenth as potent. Remifentanil can be given in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    for PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. There is no evidence that PSA using remifentanil and propofol is superior to propofol alone, nor is there evidence that either remifentanil or alfentanil is superior to fentanyl.",
"   </p>",
"   <p>",
"    When used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    for PSA,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    is given in a dose of 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    (and propofol 0.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    over one minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/79\">",
"     79",
"    </a>",
"    ]. Subsequent doses of remifentanil 0.25",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    and propofol 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may be given approximately every one to two minutes. When remifentanil is used ALONE for PSA, the initial dose is 0.5 to 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    and subsequent doses of 0.25 to 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    may be given approximately every two minutes as needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few studies have assessed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    as a sole agent for PSA and there are no published guidelines for its use in this manner. In one prospective observational study of 148 adults given alfentanil for PSA, 58 (39 percent) developed minor respiratory complications requiring intervention (eg, increased oxygen, brief bag-mask ventilation) despite achieving lighter levels of sedation than typically reached with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     Alfentanil",
"    </a>",
"    may be used as an adjunct for PSA with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and is given in a dose of 2.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    (along with propofol 0.5",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    Both may be repeated approximately every two minutes as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Coadministration of midazolam and fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;In settings where ultrashort-acting agents are unavailable, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is sometimes used for PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24,48,82,83\">",
"     24,48,82,83",
"    </a>",
"    ]. Although midazolam alone has not been shown to cause significant respiratory depression, the combination of midazolam and fentanyl can cause hypoxia and apnea, and increases the need for airway intervention and medication reversal compared with PSA using ultrashort-acting agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24,76\">",
"     24,76",
"    </a>",
"    ]. To minimize the risk of respiratory depression, some recommend that midazolam be given first and fentanyl titrated thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24\">",
"     24",
"    </a>",
"    ]. One reasonable approach to dosing these medications when they are used together is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Give",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      first: 0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 2 mg)",
"     </li>",
"     <li>",
"      Wait two minutes and observe patient response; give second dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      if necessary",
"     </li>",
"     <li>",
"      Give",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      : 0.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Observe patient; may repeat",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      dose every two minutes as necessary; titrate to effect",
"     </li>",
"     <li>",
"      Use smaller doses and longer intervals between doses in the elderly and patients with compromised hepatic or renal function",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a phencyclidine derivative that acts as a dissociative sedative. It produces a trance-like state and provides sedation, analgesia, and amnesia, while preserving upper airway muscle tone, airway protective reflexes, and spontaneous breathing. Because of its rapid onset, relatively short duration of action, and excellent sedative and analgesic properties, it is often used for brief, painful procedures, such as fracture reduction or laceration repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/64,84\">",
"     64,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is generally given IV to adults, which enables immediate onset, but it can be given intramuscularly. The duration of effect is 10 to 20 minutes. For PSA in adults, a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is given IV over one to two minutes. Doses of 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may be repeated every 5 to 10 minutes thereafter.",
"   </p>",
"   <p>",
"    According to a systematic review of 87 studies involving over 70,000 patients, significant adverse reactions rarely occur when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    is used for PSA in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/85\">",
"     85",
"    </a>",
"    ]. The authors emphasize that ketamine has proven to be an extremely safe drug despite being used frequently in &ldquo;austere, poorly monitored settings.&rdquo;",
"   </p>",
"   <p>",
"    The reported side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    include tachycardia, hypertension, laryngospasm, emergence reactions, nausea and vomiting, increased intracranial and intraocular pressure, and hypersalivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/64,85-87\">",
"     64,85-87",
"    </a>",
"    ]. Ketamine can exacerbate schizophrenia and should be avoided in patients with this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Tachycardia and hypertension are generally mild and transient, and significant cardiorespiratory events are rare.",
"   </p>",
"   <p>",
"    The risk of laryngospasm may be greater in patients with anatomic abnormalities of the upper airway (eg, tracheal stenosis, tracheomalacia) or those undergoing procedures involving significant or prolonged stimulation of the oropharynx. Guidelines published by the American College of Emergency Physicians recommend preventing secretions or blood from accumulating in the posterior oropharynx and avoiding excessive stimulation of this region with suction devices or other instruments in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    for PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emergence reactions are the most commonly reported side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/85\">",
"     85",
"    </a>",
"    ]. These reactions vary in their intensity and have been described as disorientation, dream-like experiences, or hallucinations that may be frightening. They occur in up to 20 percent of adults but can be prevented or treated by giving a small dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/2,85,90-93\">",
"     2,85,90-93",
"    </a>",
"    ]. For prevention, midazolam, approximately 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (typical adult dose 2 to 4 mg), may be given slowly (over about two minutes) by IV prior to administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Nausea and vomiting associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    administration occur in approximately 4 percent of adults. They usually occur when the patient is awake and alert and do not appear to predispose the patient to aspiration. Prophylactic treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    has met with mixed results in pediatric populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/51,94,95\">",
"     51,94,95",
"    </a>",
"    ], but pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    or comparable agents may be helpful. In one randomized trial involving PSA with ketamine, 16 of 127 children managed without antiemetics experienced post-procedural vomiting versus 6 of 128 children pretreated with ondansetron, a 7.9 percent reduction in absolute risk (95% CI 1.1-14.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    can lead to hypersalivation, which can be reduced by pretreating with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , although the benefit of such pretreatment is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbiturates suppress the reticular activating center in the brainstem and cerebral cortex, thereby causing sedation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"     Methohexital",
"    </a>",
"    is the most commonly used barbiturate for PSA, but has largely been supplanted by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"     Methohexital",
"    </a>",
"    has immediate onset, a duration of action less than 10 minutes, and provides sedation and amnesia but no analgesia. It is often given in combination with opiates, which can potentiate respiratory depression. The initial dose of methohexital is 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given intravenously; repeat doses of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV can be given every two minutes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"     Methohexital",
"    </a>",
"    causes myocardial depression, which can lead to hypotension and tachycardia. Unlike other barbiturates, methohexital can precipitate or exacerbate seizures and should be avoided in patients with a seizure disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/96\">",
"     96",
"    </a>",
"    ]. One small randomized trial found methohexital and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    to have comparable safety and efficacy when used for fracture and dislocation reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    is a barbiturate used for induction of general anesthesia, and rarely used in the performance of PSA. It is similar in efficacy and side effects to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    , but suppresses seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ketamine and propofol (ketofol)",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Ketofol\" is a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    being studied for use in PSA. The concept of ketofol is that the benefits of the two medications are synergistic and allow lower doses of each to be used. Lower doses purportedly reduce the risk for potential side effects (ie, propofol-induced hypotension and ketamine-induced vomiting and emergence reactions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of ketofol to date have not shown this combination therapy to be more efficacious or safer than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    alone when performing PSA in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/100-104\">",
"     100-104",
"    </a>",
"    ]. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial performed in the emergency department (ED) of a university teaching hospital reported no significant difference in the overall incidence of respiratory depression (the primary endpoint) between patients randomly assigned to treatment with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      for PSA",
"      <span class=\"nowrap\">",
"       (21/97;",
"      </span>",
"      22 percent) or propofol alone",
"      <span class=\"nowrap\">",
"       (27/96;",
"      </span>",
"      28 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/103\">",
"       103",
"      </a>",
"      ]. The authors report that the group given the combination of ketamine and propofol exhibited fewer episodes of apnea and oxygen desaturation and more consistent sedation, and required smaller cumulative doses of propofol. However, these differences did not achieve statistical significance and their clinical importance remains uncertain.",
"     </li>",
"     <li>",
"      A randomized, double-blind trial performed in a community hospital ED, involving 284 patients requiring PSA, reported no significant difference in adverse respiratory events between patients treated with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      (43 events) and those given propofol alone (46 events) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/105\">",
"       105",
"      </a>",
"      ]. As with the study above, the ketofol group was reported to experience more consistent sedation, as determined by sedation scale scores and the need for additional medication, but there did not appear to be important clinical differences in outcome. Patients given ketofol had less agitation during the procedure than those given propofol (5 versus 15 patients), while the opposite was true during recovery (10 versus 7 patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nitrous oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    (N2O) is an ultra-short acting agent used for PSA that is inhaled as a 30 to 50 percent mixture, with 30 percent oxygen to avoid hypoxemia. N2O has an immediate onset of action and provides analgesia, anxiolysis, and sedation. The use of N2O also obviates the need for an intravenous line. The major disadvantage to N2O is that it must be administered in a well-ventilated room with a scavenging system to prevent clinician exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few controlled studies about the use of N2O in adults have been published. Studies in children have generally found it to be safe, but it may not provide adequate analgesia for more painful procedures, such as fracture reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Future medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;New drugs are being developed that may have a future role in PSA.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24741?source=see_link\">",
"     Fospropofol",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    prodrug that may provide more sustained and consistent clinical effects at lower plasma levels than equivalent doses of propofol.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     Dexmedetomidine",
"    </a>",
"    is an alpha 2 agonist similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    that has sedative and analgesic effects. Further clinical study of these medications is needed before recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MEDICATION SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Patients without increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedural sedation and analgesia (PSA) is generally performed in relatively healthy patients who are hemodynamically stable. In such patients, we suggest that PSA be performed using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    may also be used. The relative advantages and disadvantages of each drug are discussed immediately below (",
"    <a class=\"graphic graphic_table graphicRef52744 \" href=\"mobipreview.htm?8/14/8429\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Propofol versus etomidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    have gained popularity as medications for procedural sedation and analgesia (PSA). Both medications are safe and effective in the performance of PSA, and both possess similar times to onset and recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63,107\">",
"     63,107",
"    </a>",
"    ]. Propofol may result in a higher procedural success rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63,100\">",
"     63,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors to consider when choosing between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      provides greater hemodynamic stability, as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      can cause hypotension. The fall in blood pressure from propofol is generally small and transient, but this difference may be of importance in patients with hypovolemia or hypotension who undergo PSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/108-110\">",
"       108-110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      can cause myoclonus, which appears to reduce the rate of procedural success [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63,64,111,112\">",
"       63,64,111,112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      causes dose-dependent adrenal suppression, which may be harmful in patients with severe disease (eg, sepsis, multiple trauma). Such patients may not be suitable for PSA. This effect is unlikely to be important in otherwise healthy patients.",
"     </li>",
"     <li>",
"      Respiratory depression occurs at comparable rates during PSA with both drugs, although this rarely causes harm to the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few studies have directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for PSA. In the largest such trial, 214 patients undergoing painful procedures in the emergency department were randomly assigned to sedation with either medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63\">",
"     63",
"    </a>",
"    ]. Myoclonus was more frequent with etomidate (20 versus less than 2 percent with propofol). This likely accounts for the lower rate of procedural success in the etomidate group (89 percent versus 97 percent). No clinically significant complications (eg, prolonged hypoxia) occurred in either group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41508319\">",
"    <span class=\"h3\">",
"     Propofol versus ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is more commonly used to sedate children and few studies of its role in adult procedural sedation have been performed. One small, unblinded randomized trial in adults reported higher rates of subclinical respiratory depression (as determined by changes in end-tidal CO2 or oxygen saturation), longer median times for return to baseline mental status (14 minutes versus 5 minutes), and increased agitation during recovery among patients treated with ketamine for procedural sedation compared to those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/113\">",
"     113",
"    </a>",
"    ]. The rates for clinical intervention for respiratory problems, duration of the procedure, and successful completion of the procedure did not differ between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Patients at increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some circumstances, clinicians, after carefully considering the relative risks and benefits, may elect to perform PSA in patients at increased risk of complications. Suggestions for drug selection in several common scenarios are provided here; contraindications to PSA are reviewed above (",
"    <a class=\"graphic graphic_table graphicRef52744 \" href=\"mobipreview.htm?8/14/8429\">",
"     table 2",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Contraindications and precautions'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Patients at risk of hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients at risk of hypotension due to recent illness and dehydration, cardiac disease, or some other condition, we suggest that either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    be used for PSA; in contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    has a greater blood pressure lowering effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63\">",
"     63",
"    </a>",
"    ]. Either agent will maintain hemodynamic stability. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Etomidate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Ketamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Patient at risk for airway or respiratory complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who may have a potentially difficult airway to manage or have compromised respiratory function, we suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    be used for PSA. Ketamine allows the patient to maintain protective airway reflexes and does not cause respiratory depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients are at increased risk of complications during PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, sedatives administered to older patients for PSA, regardless of the agent, should be given at a lower starting dose with slower rates of administration and less frequent dosing intervals. In elderly patients without major comorbidities or hemodynamic instability, it may be best to perform PSA using an ultrashort-acting sedative, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . Procedures in elderly patients with major comorbidities are probably best performed in the operating room. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Propofol'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Ketamine versus short-acting opioids for analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultra short-acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) provide analgesia during PSA but can contribute to respiratory depression. Some researchers hypothesize that a subdissociative dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    can provide adequate analgesia without the risk of respiratory depression.",
"   </p>",
"   <p>",
"    One small randomized trial found that patients given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    (0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    during PSA achieved similar analgesia but experienced fewer complications compared with patients given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV) and propofol, who had five times the risk of experiencing a serious adverse event (eg, hypoxia) (95% CI 1.9-13.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/99\">",
"     99",
"    </a>",
"    ]. A smaller, nonrandomized trial found that the addition of ketamine reduced pain and the need for post-procedural analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/114\">",
"     114",
"    </a>",
"    ]. Further studies are needed to confirm these preliminary findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DISCHARGE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to guide decisions about discharge following procedural sedation and analgesia (PSA). Some guidelines suggest that patients are ready for discharge when they have reached their \"neuromuscular and cognitive pre-procedure baseline\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain conditions should be met before a patient can be considered safe for discharge following PSA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The procedure should be of sufficiently low risk that additional monitoring for complications is unnecessary.",
"     </li>",
"     <li>",
"      Symptoms, such as pain, lightheadedness, and nausea should be well-controlled.",
"     </li>",
"     <li>",
"      Vital signs and respiratory and cardiac function should be stable.",
"     </li>",
"     <li>",
"      Mental status and physical function should have returned to a point where the patient can care for himself or herself with minimal to no assistance.",
"     </li>",
"     <li>",
"      A reliable person who can provide support and supervision should be present at the patient's home for at least a few hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clear written discharge instructions should be given and explained to the patient and to the family member or friend who will be assisting with the patient's care following PSA. The clinician should explain what was done, the expected course, potential problems, what to do if problems arise, when and where to follow up, and when to return to normal activities.",
"   </p>",
"   <p>",
"    One important issue is to determine a period of observation after which adverse events are sufficiently unlikely that even a patient who has not entirely returned to baseline (eg, exhibits mild drowsiness) can be discharged safely. The only study to examine the timing of significant adverse events associated with PSA was performed in a sample of 1341 children and found that 92 percent of such events occurred during the procedure, while only 8 percent occurred afterwards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/115\">",
"     115",
"    </a>",
"    ]. Significant adverse events rarely occurred more than 25 minutes after the last dose of medication was administered, provided that no adverse events had occurred up to that point. Rarely, episodes of hypoxia developed up to 40 minutes after the last medication dose. In all such cases, prior episodes of hypoxia had occurred.",
"   </p>",
"   <p>",
"    Based on these data, some clinicians believe that patients can be safely discharged within 30 minutes of receiving their last dose of sedative provided that no significant adverse events occurred during the procedure and the patient did not receive a reversal agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    ). Of note, only relatively long acting agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    were used in this study (ie, neither",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    were used). It is unlikely that a longer period of observation would be necessary following PSA with ultra-short acting agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although serious adverse events, such as hypoxia, rarely occur after discharge, it is not uncommon for patients to experience mild symptoms, such as nausea, lightheadedness, fatigue, or unsteadiness, for up to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/51/34618/abstract/5,116,117\">",
"     5,116,117",
"    </a>",
"    ]. This should be made clear to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedural sedation and analgesia (PSA) involves the use of short-acting analgesic and sedative medications to enable clinicians to perform procedures, while monitoring the patient closely for potential adverse effects. This process was previously (and inappropriately) termed \"conscious sedation.\" (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      PSA may be used for any procedure in which a patient's pain or anxiety may be excessive and may impede performance. There are no absolute contraindications to PSA. Relative contraindications include: older age, significant medical comorbidities, and signs of a difficult airway. Whether the patient recently ate should be considered before performing PSA, although this may not increase aspiration risk. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The number of clinicians needed to perform PSA and the procedure safely may vary according to the patient and the procedure. In most cases, one clinician performs the procedure while another (usually a nurse) administers the sedative agents and monitors and records the patient's vital signs and clinical status. Whenever possible, we suggest that this minimum standard be met. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prerequisites and personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper monitoring during PSA is crucial. The patient's blood pressure, heart rate, and respiratory rate should be measured at frequent, regular intervals; oxygen saturation (SpO2), end-tidal carbon dioxide level (EtCO2), and cardiac rhythm should be monitored continuously. We suggest that high flow oxygen (15 L by face mask) be provided to patients receiving PSA. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring and preoxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious complications attributable to PSA rarely occur. Significant respiratory compromise develops in less than 1 percent of cases. Adverse outcomes may include respiratory depression with hypoxia or hypercarbia, cardiovascular instability, vomiting and aspiration, and inadequate sedation preventing completion of the procedure. All equipment and medications necessary for airway management should be at the bedside during PSA. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ideal drugs for PSA have a rapid onset and short duration of action, maintain hemodynamic stability, and do not cause major side effects. Several medications are commonly used and no single drug is ideal for all situations (",
"      <a class=\"graphic graphic_table graphicRef52744 \" href=\"mobipreview.htm?8/14/8429\">",
"       table 2",
"      </a>",
"      ). Medications used for PSA are discussed in the text. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PSA is most often performed in patients without major comorbidities or hemodynamic instability. In such patients, we suggest that PSA be performed using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      may also be used. The relative advantages and disadvantages of each drug are discussed in the text. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Patients without increased risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older patients are at increased risk of complications during PSA. Therefore, sedatives administered to older patients for PSA, regardless of the agent, should be given using a lower starting dose, slower rates of administration, and less frequent dosing intervals. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Elderly patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some circumstances, clinicians, after carefully considering the relative risks and benefits, may elect to perform PSA in patients at some increased risk of complications. In patients at risk of hypotension, we suggest that either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      be used for PSA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who may have a potentially difficult airway or have compromised respiratory function, we suggest that ketamine be used for PSA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Patients at increased risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for safe discharge following PSA are described in the text. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Discharge criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/1\">",
"      Green SM, Krauss B. Procedural sedation terminology: moving beyond \"conscious sedation\". Ann Emerg Med 2002; 39:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/2\">",
"      Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/3\">",
"      American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002; 96:1004.",
"     </a>",
"    </li>",
"    <li>",
"     Joint Commission on Accreditation of Healthcare Organizations. Comprehensive Accreditation Manual for Hospitals, The Official Handbood. JCAHO Publication, Chicago 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/5\">",
"      Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med 2000; 342:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/6\">",
"      Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev 2003; :CD004423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/7\">",
"      Cheung KW, Watson ML, Field S, Campbell SG. Aspiration pneumonitis requiring intubation after procedural sedation and analgesia: a case report. Ann Emerg Med 2007; 49:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/8\">",
"      Sakai T, Planinsic RM, Quinlan JJ, et al. The incidence and outcome of perioperative pulmonary aspiration in a university hospital: a 4-year retrospective analysis. Anesth Analg 2006; 103:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/9\">",
"      Mace SE. Adverse events of emergency department procedural sedation. [abstract] Ann Emerg Med 2006; 48:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/10\">",
"      Miller MA, Levy P, Patel MM. Procedural sedation and analgesia in the emergency department: what are the risks? Emerg Med Clin North Am 2005; 23:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/11\">",
"      Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003; 74:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/12\">",
"      Miner JR, Burton JH. Clinical practice advisory: Emergency department procedural sedation with propofol. Ann Emerg Med 2007; 50:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/13\">",
"      Green SM, Krauss B. Pulmonary aspiration risk during emergency department procedural sedation--an examination of the role of fasting and sedation depth. Acad Emerg Med 2002; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/14\">",
"      Splinter WM, Stewart JA, Muir JG. Large volumes of apple juice preoperatively do not affect gastric pH and volume in children. Can J Anaesth 1990; 37:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/15\">",
"      Green SM. Fasting is a consideration--not a necessity--for emergency department procedural sedation and analgesia. Ann Emerg Med 2003; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/16\">",
"      Sandhar BK, Goresky GV, Maltby JR, Shaffer EA. Effect of oral liquids and ranitidine on gastric fluid volume and pH in children undergoing outpatient surgery. Anesthesiology 1989; 71:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/17\">",
"      Ljungqvist O, S&oslash;reide E. Preoperative fasting. Br J Surg 2003; 90:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/18\">",
"      Green SM, Roback MG, Miner JR, et al. Fasting and emergency department procedural sedation and analgesia: a consensus-based clinical practice advisory. Ann Emerg Med 2007; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/19\">",
"      S&oslash;reide E, Eriksson LI, Hirlekar G, et al. Pre-operative fasting guidelines: an update. Acta Anaesthesiol Scand 2005; 49:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/20\">",
"      Brady M, Kinn S, O'Rourke K, et al. Preoperative fasting for preventing perioperative complications in children. Cochrane Database Syst Rev 2005; :CD005285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/21\">",
"      Engelhardt T, Webster NR. Pulmonary aspiration of gastric contents in anaesthesia. Br J Anaesth 1999; 83:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/22\">",
"      Olsson GL, Hallen B, Hambraeus-Jonzon K. Aspiration during anaesthesia: a computer-aided study of 185,358 anaesthetics. Acta Anaesthesiol Scand 1986; 30:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/23\">",
"      Blitt CD, Gutman HL, Cohen DD, et al. \"Silent\" regurgitation and aspiration during general anesthesia. Anesth Analg 1970; 49:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/24\">",
"      Godwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med 2005; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/25\">",
"      Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol for procedural sedation in children in the emergency department. Ann Emerg Med 2003; 42:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/26\">",
"      Harrington L. Nurse-administered propofol sedation: a review of current evidence. Gastroenterol Nurs 2006; 29:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/27\">",
"      Cot&eacute; CJ, Notterman DA, Karl HW, et al. Adverse sedation events in pediatrics: a critical incident analysis of contributing factors. Pediatrics 2000; 105:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/28\">",
"      Hogan K, Sacchetti A, Aman L, Opiela D. The safety of single-physician procedural sedation in the emergency department. Emerg Med J 2006; 23:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/29\">",
"      Deitch K, Chudnofsky CR, Dominici P, et al. The utility of high-flow oxygen during emergency department procedural sedation and analgesia with propofol: a randomized, controlled trial. Ann Emerg Med 2011; 58:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/30\">",
"      Deitch K, Chudnofsky CR, Dominici P. The utility of supplemental oxygen during emergency department procedural sedation and analgesia with midazolam and fentanyl: a randomized, controlled trial. Ann Emerg Med 2007; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/31\">",
"      Miner JR, Biros MH, Heegaard W, Plummer D. Bispectral electroencephalographic analysis of patients undergoing procedural sedation in the emergency department. Acad Emerg Med 2003; 10:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/32\">",
"      Miner JR, Heegaard W, Plummer D. End-tidal carbon dioxide monitoring during procedural sedation. Acad Emerg Med 2002; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/33\">",
"      McQuillen KK, Steele DW. Capnography during sedation/analgesia in the pediatric emergency department. Pediatr Emerg Care 2000; 16:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/34\">",
"      Sivilotti ML, Messenger DW, van Vlymen J, et al. A comparative evaluation of capnometry versus pulse oximetry during procedural sedation and analgesia on room air. CJEM 2010; 12:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/35\">",
"      Anderson JL, Junkins E, Pribble C, Guenther E. Capnography and depth of sedation during propofol sedation in children. Ann Emerg Med 2007; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/36\">",
"      Deitch K, Chudnofsky CR, Dominici P. Can emergency physicians recognize respiratory depression in patients who do not become hypoxic during ED procedural sedation and analgesia? Ann Emerg Med 2007; 50:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/37\">",
"      Deitch K, Miner J, Chudnofsky CR, et al. Does end tidal CO2 monitoring during emergency department procedural sedation and analgesia with propofol decrease the incidence of hypoxic events? A randomized, controlled trial. Ann Emerg Med 2010; 55:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/38\">",
"      Wright SW. Conscious sedation in the emergency department: the value of capnography and pulse oximetry. Ann Emerg Med 1992; 21:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/39\">",
"      Gill M, Green SM, Krauss B. A study of the Bispectral Index Monitor during procedural sedation and analgesia in the emergency department. Ann Emerg Med 2003; 41:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/40\">",
"      American Society of Anesthesiologists Task Force on Intraoperative Awareness. Practice advisory for intraoperative awareness and brain function monitoring: a report by the american society of anesthesiologists task force on intraoperative awareness. Anesthesiology 2006; 104:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/41\">",
"      Niedhart DJ, Kaiser HA, Jacobsohn E, et al. Intrapatient reproducibility of the BISxp monitor. Anesthesiology 2006; 104:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/42\">",
"      Clinical policy for procedural sedation and analgesia in the emergency department. American College of Emergency Physicians. Ann Emerg Med 1998; 31:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/43\">",
"      Pe&ntilde;a BM, Krauss B. Adverse events of procedural sedation and analgesia in a pediatric emergency department. Ann Emerg Med 1999; 34:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/44\">",
"      Rothermel LK. Newer pharmacologic agents for procedural sedation of children in the emergency department-etomidate and propofol. Curr Opin Pediatr 2003; 15:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/45\">",
"      Skokan EG, Pribble C, Bassett KE, Nelson DS. Use of propofol sedation in a pediatric emergency department: a prospective study. Clin Pediatr (Phila) 2001; 40:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/46\">",
"      Tomicheck RC, Rosow CE, Philbin DM, et al. Diazepam-fentanyl interaction--hemodynamic and hormonal effects in coronary artery surgery. Anesth Analg 1983; 62:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/47\">",
"      Blackburn P, Vissers R. Pharmacology of emergency department pain management and conscious sedation. Emerg Med Clin North Am 2000; 18:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/48\">",
"      Pitetti RD, Singh S, Pierce MC. Safe and efficacious use of procedural sedation and analgesia by nonanesthesiologists in a pediatric emergency department. Arch Pediatr Adolesc Med 2003; 157:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/49\">",
"      Vinson DR, Bradbury DR. Etomidate for procedural sedation in emergency medicine. Ann Emerg Med 2002; 39:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/50\">",
"      Chew ST, Ip-Yam PC, Kong CF. Recovery following tonsillectomy a comparison between tramadol and morphine for analgesia. Singapore Med J 2003; 44:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/51\">",
"      Roback MG, Wathen JE, Bajaj L, Bothner JP. Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs. Acad Emerg Med 2005; 12:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/52\">",
"      Langston WT, Wathen JE, Roback MG, Bajaj L. Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. Ann Emerg Med 2008; 52:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/53\">",
"      Swanson ER, Seaberg DC, Mathias S. The use of propofol for sedation in the emergency department. Acad Emerg Med 1996; 3:234.",
"     </a>",
"    </li>",
"    <li>",
"     Diprivan (propofol): manufacturer's package insert. US National Library of Medicine www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4756#section-11 (Accessed on May 26, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/55\">",
"      Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother 2003; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/56\">",
"      Jalota L, Kalira V, George E, et al. Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ 2011; 342:d1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/57\">",
"      Miner JR, Gray RO, Stephens D, Biros MH. Randomized clinical trial of propofol with and without alfentanil for deep procedural sedation in the emergency department. Acad Emerg Med 2009; 16:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/58\">",
"      Walker JA, McIntyre RD, Schleinitz PF, et al. Nurse-administered propofol sedation without anesthesia specialists in 9152 endoscopic cases in an ambulatory surgery center. Am J Gastroenterol 2003; 98:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/59\">",
"      Tohda G, Higashi S, Sakumoto H, et al. Efficacy and safety of nurse-administered propofol sedation during emergency upper endoscopy for gastrointestinal bleeding: a prospective study. Endoscopy 2006; 38:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/60\">",
"      Green SM, Krauss B. Barriers to propofol use in emergency medicine. Ann Emerg Med 2008; 52:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/61\">",
"      Flynn G. \"Poachers and dabblers?\": ASA president's incautious comment riles emergency physicians. Ann Emerg Med 2007; 50:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/62\">",
"      Weaver JM. The great debate on nurse-administered propofol sedation (NAPS)--where should we stand? Anesth Prog 2006; 53:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/63\">",
"      Miner JR, Danahy M, Moch A, Biros M. Randomized clinical trial of etomidate versus propofol for procedural sedation in the emergency department. Ann Emerg Med 2007; 49:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/64\">",
"      Brown TB, Lovato LM, Parker D. Procedural sedation in the acute care setting. Am Fam Physician 2005; 71:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/65\">",
"      Falk J, Zed PJ. Etomidate for procedural sedation in the emergency department. Ann Pharmacother 2004; 38:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/66\">",
"      Sacchetti A, Senula G, Strickland J, Dubin R. Procedural sedation in the community emergency department: initial results of the ProSCED registry. Acad Emerg Med 2007; 14:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/67\">",
"      Keim SM, Erstad BL, Sakles JC, Davis V. Etomidate for procedural sedation in the emergency department. Pharmacotherapy 2002; 22:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/68\">",
"      Doenicke AW, Roizen MF, Kugler J, et al. Reducing myoclonus after etomidate. Anesthesiology 1999; 90:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/69\">",
"      Burton JH, Bock AJ, Strout TD, Marcolini EG. Etomidate and midazolam for reduction of anterior shoulder dislocation: a randomized, controlled trial. Ann Emerg Med 2002; 40:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/70\">",
"      Ruth WJ, Burton JH, Bock AJ. Intravenous etomidate for procedural sedation in emergency department patients. Acad Emerg Med 2001; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/71\">",
"      H&uuml;ter L, Schreiber T, Gugel M, Schwarzkopf K. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion. Anesth Analg 2007; 105:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/72\">",
"      Guler A, Satilmis T, Akinci SB, et al. Magnesium sulfate pretreatment reduces myoclonus after etomidate. Anesth Analg 2005; 101:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/73\">",
"      Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/74\">",
"      Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/75\">",
"      Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. Gastrointest Endosc Clin N Am 2004; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/76\">",
"      Bahn EL, Holt KR. Procedural sedation and analgesia: a review and new concepts. Emerg Med Clin North Am 2005; 23:503.",
"     </a>",
"    </li>",
"    <li>",
"     Muse DA. Conscious and deep sedation. In: The Clinical Practice of Emergency Medicine, 3rd ed, Harwood-Nuss, A, Wolfson, AB (Eds), Lippincott, Williams and Wilkins, Philadelphia 2001. p.1761.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/78\">",
"      Phillips WJ, Halpin J, Jones J, McKenzie K. Remifentanil for procedural sedation in the emergency department. Ann Emerg Med 2009; 53:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/79\">",
"      Dunn MJ, Mitchell R, Souza CD, Drummond G. Evaluation of propofol and remifentanil for intravenous sedation for reducing shoulder dislocations in the emergency department. Emerg Med J 2006; 23:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/80\">",
"      Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/81\">",
"      Miner JR, Gray R, Delavari P, et al. Alfentanil for procedural sedation in the emergency department. Ann Emerg Med 2011; 57:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/82\">",
"      Campbell SG, Magee KD, Kovacs GJ, et al. Procedural sedation and analgesia in a Canadian adult tertiary care emergency department: a case series. CJEM 2006; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/83\">",
"      Ab-Rahman NH, Hashim A. A randomized controlled trial on procedural sedation among adult patients in emergency departments: comparing fentanyl with midazolam versus fentanyl with propofol [abstract]. Ann Emerg Med 2008; 51:479.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston MN, Liebelt EL. Acute pain management and procedural sedation in children. In: Emergency Medicine: A Comprehensive Study Guide, 6th Ed, Tintinalli, JE, Kelen, GD, Stapczynski, JS (Eds), McGraw-Hill, New York 2004. p.858.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/85\">",
"      Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am J Emerg Med 2008; 26:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/86\">",
"      Newton A, Fitton L. Intravenous ketamine for adult procedural sedation in the emergency department: a prospective cohort study. Emerg Med J 2008; 25:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/87\">",
"      Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011; 57:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/88\">",
"      Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/89\">",
"      Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/90\">",
"      Mason KP, Michna E, DiNardo JA, et al. Evolution of a protocol for ketamine-induced sedation as an alternative to general anesthesia for interventional radiologic procedures in pediatric patients. Radiology 2002; 225:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/91\">",
"      Chudnofsky CR, Weber JE, Stoyanoff PJ, et al. A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients. Acad Emerg Med 2000; 7:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/92\">",
"      Vardy JM, Dignon N, Mukherjee N, et al. Audit of the safety and effectiveness of ketamine for procedural sedation in the emergency department. Emerg Med J 2008; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/93\">",
"      Sener S, Eken C, Schultz CH, et al. Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial. Ann Emerg Med 2011; 57:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/94\">",
"      Wathen JE, Roback MG, Mackenzie T, Bothner JP. Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial. Ann Emerg Med 2000; 36:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/95\">",
"      Thorp AW, Brown L, Green SM. Ketamine-associated vomiting: is it dose-related? Pediatr Emerg Care 2009; 25:15.",
"     </a>",
"    </li>",
"    <li>",
"     Nicolaou DD. Procedural sedation and analgesia. In: Emergency Medicine: A Comprehensive Study Guide, 6th Ed, Tintinalli, JE, Kelen, GK, Stapczynski, JS (Eds), McGraw-Hill, New York 2004. p.275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/97\">",
"      Miner JR, Biros M, Krieg S, et al. Randomized clinical trial of propofol versus methohexital for procedural sedation during fracture and dislocation reduction in the emergency department. Acad Emerg Med 2003; 10:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/98\">",
"      Willman EV, Andolfatto G. A prospective evaluation of \"ketofol\" (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. Ann Emerg Med 2007; 49:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/99\">",
"      Messenger DW, Murray HE, Dungey PE, et al. Subdissociative-dose ketamine versus fentanyl for analgesia during propofol procedural sedation: a randomized clinical trial. Acad Emerg Med 2008; 15:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/100\">",
"      Green SM. Research advances in procedural sedation and analgesia. Ann Emerg Med 2007; 49:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/101\">",
"      Loh G, Dalen D. Low-dose ketamine in addition to propofol for procedural sedation and analgesia in the emergency department. Ann Pharmacother 2007; 41:485.",
"     </a>",
"    </li>",
"    <li>",
"     Aurora, S. Combining ketamine and propofol (\"ketofol\") for emergency department procedural sedation and analgesia: a review. West J Emerg Med 2008; 9: Article 5 repositories.cdlib.org/uciem/westjem/vol9/iss1/art5 (Accessed on June 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/103\">",
"      David H, Shipp J. A randomized controlled trial of ketamine/propofol versus propofol alone for emergency department procedural sedation. Ann Emerg Med 2011; 57:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/104\">",
"      Phillips W, Anderson A, Rosengreen M, et al. Propofol versus propofol/ketamine for brief painful procedures in the emergency department: clinical and bispectral index scale comparison. J Pain Palliat Care Pharmacother 2010; 24:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/105\">",
"      Andolfatto G, Abu-Laban RB, Zed PJ, et al. Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial. Ann Emerg Med 2012; 59:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/106\">",
"      Babl FE, Oakley E, Puspitadewi A, Sharwood LN. Limited analgesic efficacy of nitrous oxide for painful procedures in children. Emerg Med J 2008; 25:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/107\">",
"      Gillies GW, Lees NW. The effects of speed of injection on induction with propofol. A comparison with etomidate. Anaesthesia 1989; 44:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/108\">",
"      Burton JH, Miner JR, Shipley ER, et al. Propofol for emergency department procedural sedation and analgesia: a tale of three centers. Acad Emerg Med 2006; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/109\">",
"      Guenther E, Pribble CG, Junkins EP Jr, et al. Propofol sedation by emergency physicians for elective pediatric outpatient procedures. Ann Emerg Med 2003; 42:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/110\">",
"      Coll-Vinent B, Sala X, Fern&aacute;ndez C, et al. Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med 2003; 42:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/111\">",
"      Plewa MC, King R, Johnson D, et al. Etomidate use during emergency intubation of trauma patients. Am J Emerg Med 1997; 15:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/112\">",
"      Kociszewski C, Thomas SH, Harrison T, Wedel SK. Etomidate versus succinylcholine for intubation in an air medical setting. Am J Emerg Med 2000; 18:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/113\">",
"      Miner JR, Gray RO, Bahr J, et al. Randomized clinical trial of propofol versus ketamine for procedural sedation in the emergency department. Acad Emerg Med 2010; 17:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/114\">",
"      Mortero RF, Clark LD, Tolan MM, et al. The effects of small-dose ketamine on propofol sedation: respiration, postoperative mood, perception, cognition, and pain. Anesth Analg 2001; 92:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/115\">",
"      Newman DH, Azer MM, Pitetti RD, Singh S. When is a patient safe for discharge after procedural sedation? The timing of adverse effect events in 1367 pediatric procedural sedations. Ann Emerg Med 2003; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/116\">",
"      Malviya S, Voepel-Lewis T, Tait AR. Adverse events and risk factors associated with the sedation of children by nonanesthesiologists. Anesth Analg 1997; 85:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/51/34618/abstract/117\">",
"      Malviya S, Voepel-Lewis T, Prochaska G, Tait AR. Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children. Pediatrics 2000; 105:E42.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 264 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34618=[""].join("\n");
var outline_f33_51_34618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Aspiration risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PERFORMING PROCEDURAL SEDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prerequisites and personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring and preoxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Considerations in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Propofol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Etomidate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Benzodiazepines (midazolam)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Short-acting opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Coadministration of midazolam and fentanyl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ketamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ketamine and propofol (ketofol)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nitrous oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Future medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MEDICATION SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Patients without increased risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Propofol versus etomidate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41508319\">",
"      - Propofol versus ketamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Patients at increased risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Patients at risk of hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Patient at risk for airway or respiratory complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Ketamine versus short-acting opioids for analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DISCHARGE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/264|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/33/8733\" title=\"table 1\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/14/8429\" title=\"table 2\">",
"      Medications for adult procedural sedation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_51_34619="Indications for antepartum fetal surveillance";
var content_f33_51_34619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for antepartum fetal surveillance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiphospholipid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly controlled hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanotic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 1 diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pregnancy complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased fetal movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oligohydramnios",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyhydramnios",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrauterine growth restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postterm pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoimmunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous unexplained fetal demise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple gestation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in American College of Obstetricians and Gynecologists. Antepartum fetal surveillance. Practice Bulletin #9, October 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34619=[""].join("\n");
var outline_f33_51_34619=null;
var title_f33_51_34620="Ethanol intoxication in children - Rapid overview";
var content_f33_51_34620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ethanol intoxication in children: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure that \"alcohol\" ingested is ethanol and not another toxic alcohol (eg, methanol, ethylene glycol): clinical signs of toxic alcohol include a serum osmolal gap out of proportion to the ethanol level soon after ingestion, and delayed onset of severe anion gap metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol ingestion in young children carries a significant risk for hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Common findings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vital signs - hypothermia, bradycardia, hypotension, and/or respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other - lethargy, coma, ataxia, slurred speech, vomiting, and/or sweet breath odor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other findings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoglycemic seizures and death (especially young children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mild to moderate hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Signs of trauma or sexual assault (adolescents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain fingerstick blood glucose in all patients with altered mental status and young children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measure blood ethanol level*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible toxic alcohol ingestion: serum electrolytes, BUN, creatinine, serum osmolality, serum calcium, blood gas, serum methanol and ethylene glycol levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other studies based on clinical presentation (see text)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure airway and support breathing as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat hypoglycemia with 0.25 g/kg IV dextrose bolus followed by continuous dextrose infusion with &frac14; or &frac12; normal saline, depending upon maintenance sodium requirements, to maintain blood glucose greater than 60 mg/dL (3.33 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat hypovolemia with intravenous bolus of normal saline or lactated Ringer's solution 20 mL/kg (maximum 1 L), repeat as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rewarm based on core body temperature",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All infants and young children with significant ingestion. May provide estimate of symptom duration in moderate to severely intoxicated adolescents.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34620=[""].join("\n");
var outline_f33_51_34620=null;
var title_f33_51_34621="USPSTF Chlamydia screening recommendations";
var content_f33_51_34621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    USPSTF recommendations for screening for Chlamydial infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"11%\">",
"     </colgroup>",
"     <colgroup width=\"19%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"19%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Nonpregnant women",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Pregnant women",
"       </td>",
"       <td class=\"subtitle1\">",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Population",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 24 years or younger",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Age 25 years or older",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 24 years or younger",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Age 25 years or older",
"       </td>",
"       <td class=\"centered\" rowspan=\"3\">",
"        <p>",
"         &nbsp;",
"        </p>",
"        No recommendation due to insufficient evidence*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Includes adolescents",
"       </td>",
"       <td>",
"        Not at increased risk",
"       </td>",
"       <td>",
"        At increased risk",
"       </td>",
"       <td>",
"        Includes adolescents",
"       </td>",
"       <td>",
"        Not at increased risk",
"       </td>",
"       <td>",
"        At increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Recommendation",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         A",
"        </p>",
"        Screen if sexually active",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        <p>",
"         A",
"        </p>",
"        Screen if sexually active",
"       </td>",
"       <td>",
"        <p>",
"         B",
"        </p>",
"        Screen",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        <p>",
"         B",
"        </p>",
"        Screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Risk assessment",
"        </strong>",
"       </td>",
"       <td colspan=\"7\">",
"        <p>",
"         <strong>",
"          Age:",
"         </strong>",
"         Women and men age 24 years or younger are at greatest risk.",
"        </p>",
"        <p>",
"         <strong>",
"          History of:",
"         </strong>",
"         Previous chlamydial infection or other sexually transmitted infections, new or multiple sexual partners, inconsistent condom use, sex work.",
"        </p>",
"        <strong>",
"         Demographics:",
"        </strong>",
"        African-American and Hispanic women and men have higher prevalence rates than the general population in many communities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Screening tests",
"        </strong>",
"       </td>",
"       <td colspan=\"7\">",
"        Nucleic acid amplification tests (NAATs) can identify chlamydial infection in asymptomatic women (nonpregnant and pregnant) and asymptomatic men. NAATs have high specificity and sensitivity and can be used with urine and vaginal swabs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Screening intervals",
"        </strong>",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"3\">",
"        Nonpregnant women",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"3\">",
"        Pregnant women",
"       </td>",
"       <td class=\"subtitle3\">",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        The optimal interval for screening is not known. The Centers for Disease Control and Prevention (CDC) recommends that women at increased risk be screened at least annually.",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td colspan=\"3\">",
"        Women 24 years or younger and older women at increased risk: Screen at the first prenatal visit.",
"        <br/>",
"        Patients at continuing risk or who are newly at risk: Screen in the third trimester.",
"       </td>",
"       <td class=\"centered\">",
"        Not applicable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"sublist_other\" colspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td colspan=\"7\">",
"        The USPSTF recommends the service. There is high certainty that the net benefit is substantial.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"       </td>",
"       <td colspan=\"7\">",
"        The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or there is moderate certainty that the net benefit is moderate to substantial.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td colspan=\"7\">",
"        The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td colspan=\"7\">",
"        The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to www.preventiveservices.ahrq.gov.",
"    <div class=\"footnotes\">",
"     USPSTF: United States Preventive Services Task Force.",
"     <br/>",
"     * Chlamydial infection results in few squelae in men. Therefore, the major benefit of screening men would be to reduce the likelihood that infected and untreated men would pass the infection on to sexual partners. There is no evidence that screening men reduces the long-term consequences of chlamydial infection in women. Because of this lack of evidence, the USPSTF could not assess the balance of benefits and harms and concluded that the evidence is insufficient to recommend for or against routinely screening men.",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br/>",
"     <ol>",
"      <li>",
"       Information from: Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"      </li>",
"     </ol>",
"     <br/>",
"     Reproduced with permission from: U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 147:128. Copyright &copy; 2007 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34621=[""].join("\n");
var outline_f33_51_34621=null;
var title_f33_51_34622="Pregnancy due date calculator";
var content_f33_51_34622=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pregnancy due date calculator (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/51/34622/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34622/contributors\" id=\"au5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/51/34622/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34622/contributors\" id=\"se1618\">",
"       Louis Leff, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/51/34622/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/51/34622/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/51/34622?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      WHAT IS MY DUE DATE?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Due date calculator",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have regular monthly menstrual cycles and know the first day of your last menstrual period, you can determine when your baby is due by using the following calculator (",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?21/15/21759?source=see_link\">",
"      calculator 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you do not have regular monthly menstrual cycles or do not know when your last menstrual period started or when you conceived, you will need to have an ultrasound examination to determine your due date. This examination should be done as soon as possible because ultrasounds done after the fourth to fifth month of pregnancy are not very reliable for predicting due dates.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/51/34622?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_51_34622=[""].join("\n");
var outline_f33_51_34622=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           WHAT IS MY DUE DATE?",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?21/15/21759?source=related_link\" title=\"calculator 1\">",
"           Calculator: Estimated Date of Delivery (EDD) (Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_51_34623="Cardiac auscultation supine and leaning forward";
var content_f33_51_34623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Cardiac auscultation supine and leaning forward",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Auscultation of the pericardium: To elicit pericardial rubs, the patient is invited to lean forward (A) or rest on elbows and knees (B). Both physical maneuvers increase the contact of visceral and parietal pericardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Heart, Imazio M. Pericardial involvement in systemic inflammatory diseases, 97:1882, Copyright &copy; 2011, with permission from BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_51_34623=[""].join("\n");
var outline_f33_51_34623=null;
